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A Bioethics-Centered Argument in Favor of  
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 Ernest R. and Iris M. Eldred Professor of Law, Paul M. Herbert Law Center, Louisiana State University.  JD Yale 
Law School; BA, summa cum laude, Tufts University.  This article was selected by international, interdisciplinary 
peer review for presentation at “One Origin, One Race, One Earth: Genetics, Human Rights and the Next Phase of 
Human Evolution,” which was hosted by the University of Calgary on November 15-17, 2007.  My sincere 
appreciation to event co-chairs Brian Seaman and Rose Geransar, and to all whose interactions greatly enriched this 
manuscript.  The article also has benefited from participation in several additional events and presentations, most 
notably those given at a meeting hosted by Academia Sinica to launch the Taiwan Biobank, held in Taipei, Taiwan, 
August 2007, and the 21st Century Trust forum on genomics held at the Wellcome Trust’s Sanger Institute, 
Cambridge, England, in August 2006.  The present version will be discussed at “Ancestry in Health and Medicine 
Workshop: Expanding the Debate,” a roundtable event to be held in Toronto April 8-9, 2008.  My appreciation to 
the organizers of and participants in these events, and to colleagues Carl Coleman, Donna Gitter, Jonathan Kahn, 
and David Winickoff, who shared their expertise in the field and, as always, were generous with their time.  Their 
contributions enriched this effort immensely.  I also would like to thank Jim Figura and Damon Bowe for their 
excellent research assistance and thoughtful editorial input.     
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Oct. 14, 2007 
[Dr. James Watson, co-discoverer of the structure of DNA,] says that he is “inherently 
gloomy about the prospect of Africa” because “all our social policies are based on the 
fact that their intelligence is the same as ours—whereas all the testing says not really’, 
and I know that this “hot potato” is going to be difficult to address.  His hope is that 
everyone is equal, but he counters that “people who have to deal with black employees 
find this not true”.  He says that you should not discriminate on the basis of colour, 
because “there are many people of colour who are very talented, but don’t promote them 
when they haven’t succeeded at the lower level”.  He writes that “there is no firm reason 
to anticipate that the intellectual capacities of peoples geographically separated in their 
evolution should prove to have evolved identically.  Our wanting to reserve equal powers 
of reason as some universal heritage of humanity will not be enough to make it so”.1
Oct. 18, 2007 
The Federation of American Scientists (FAS) is outraged by the noxious comments of Dr. 
James Watson that appeared in the Sunday [London] Times Magazine on October 14th. 
At a time when the scientific community is feeling threatened by political forces seeking 
to undermine its credibility it is tragic that one of the icons of modern science has cast 
such dishonor on the profession.  
 
1 Charlotte Hunt-Grubbe, The elementary DNA of Dr. Watson, THE SUN. TIMES, Oct. 14, 2007, at __. 
 
3The scientific enterprise is based on the promotion and proof of new ideas through 
evidence, however controversial, but Dr. Watson chose to use his unique stature to 
promote personal prejudices that are racist, vicious and unsupported by science. 
While we honor the extraordinary contributions that Dr. Watson has made to science in 
the past, his comments show that he has lost his way. He has failed us in the worst 
possible way. It is a sad and revolting way to end a remarkable career.2
Oct. 18, 2007 
Earlier this evening, the Cold Spring Harbor Laboratory Board of Trustees Decided to 
Suspend the Administrative Responsibilities of Chancellor James D. Watson, Ph.D., 
pending further deliberation by the Board. 
 
This action follows the Board’s public statement yesterday disagreeing with the 
comments attributed to Dr. Watson in the October 14, 2007 edition of The Sunday Times 
U.K.3
I.  Introduction 
 
2 The Federation of American Scientists Condemns the Comments of Dr. James Watson that Appeared in the Sunday 
Times Magazine on Oct. 14th, available at http://fas.org/main/content.jsp?formAction=297&contentId=572. 
 
3 Statement by Cold Spring Harbor Board of Trustees and President Bruce Stillman, Ph.D. Regarding Dr. Watson’s 
Comments in The Sunday Times October 14, 2007, available at 
http://www.cshl.edu/public/releases/07_statement2.html 
 
4“Race” and “ethnicity” compel reaction.4 These concepts are social constructs,5 and 
many commentators—drawing from a portfolio of disciplines that includes the natural sciences, 
the social sciences, medicine, and law—argue that the human population groupings they form 
 
4 The research, writing, and completion of this article coincides with a raw national debate over race, brought to a 
simmer and then beyond by a series of controversies.  Race and gender charged the Democratic primary race 
between candidates Sen. Clinton and Sen. Obama.  See Adam Nagourney, Democrats Vote Reveals Deep Split 
Obama and Clinton Supporters Differ in Age, Race, and Gender, INT’L HERALD TRIB., Feb. 8. 2008, at 5.  During 
spring 2007, radio personality Don Imus was fired for racial and sexist remarks about the Rutgers University 
women’s basketball team.  See Dahleen Glanton, Civil Rights Group Has Eye on Prize of Peace: Nation, CHICAGO 
TRIBUNE, Aug. 3, 2007 (page nos. not available), 2007 WLNR 14904150.  Soon after, charges from an alleged rape 
brought by an African American woman against Caucasian members of the Duke University male lacrosse team 
were dropped and the prosecutor himself faced charges.  See Glanton, Civil Rights Group, supra; David Zucchino, 
The Nation: Ex-Duke Players Get New Apology, LA TIMES, July 27, 2007, at 13.  Then, On September 20, the 
nation’s attention was drawn to the small town of Jena, Louisiana, self-proclaimed to be “a nice place to call home,” 
as more than 20,000 participated in a march led by the Reverand Jesse Jasckson and Al Sharpton.  See Black 
Leadership in America: Race, Justice and Jena, ECONOMIST, Sept. 2007, at 71, 2007 WLNR 18968014 (no author 
identified).  According to a report in the Economist,
At a high school assembly on August 30th [2006], a black student asked if he could sit under a shady tree on 
campus where the white students usually hung out.  The deputy principal said of course he could sit 
wherever he wanted.  The next day, two nooses dangled from the tree.  They were quickly removed, and 
the principal recommended that the three white students who hung them be expelled.  But the school board 
let them off with a suspension, arguing that the incident was just a childish prank. . . . .  On December 4th a 
black student named Mychal Bell jumped a white classmate from behind and knocked him out.  Then he 
and six others kicked him as he lay on the ground.   He was released in time to go out that evening, but 
retired home early complaining of pain.  Five of the attackers were charged with attempted second-degree 
murder.  That caused an outcry, so the charges were reduced to second-degree battery, which still carries 
heavy penalties.  Mr. Bell was tried as an adult, though he was only 16 at the time of the attack.  The 
prosecutor says this was because he had been arrested four times before for violent offences.  He was 
convicted by an all-white jury.  (Several blacks were summoned for jury duty, but non showed up.)  . . . .   
But a higher court threw out his conviction and ordered that he be tried as a juvenile. 
 
Id. (page numbers unavailable).  Even before the House Judiciary Committee could hold a hearing on the “Jena Six” 
controversy (which took place on October 17, 2007), media reported on September 30 that a maintenance man found 
a noose hanging in the Hempstead, Long Island police department.  See Joe Gould & Carrie Melago, Noose Found 
Hanging in L.I. Police Station, N.Y. DAILY NEWS, Sept 30, 2007, at 10; Dana Millbank, Justice Denied, Sharpton 
Delayed, WASH. POST, Oct. 17, 2007 (page numbers unavailable), 2007 WLNR 20337642.  On October 13, a noose 
also was found hanging on the door of Professor Madonna Constantine, a black professor of psychology at 
Columbia University, and other “noose incidents” started arising across the nation.  See Lester Holt, Profile: In 
Depth; Nooses, an Old Symbol of Hate, Making Comeback, NBC NEWS: NIGHTLY NEWS, Oct. 13, 2007 (page 
numbers unavailable).  These incidents were two of more than forty (40) noose hanging incidents across the country 
during fall 2007.  See Mark Potok, Luke Visconti, Barbara Frankel, & Nigel Holmes, The Geography of Hate, 
N.Y.TIMES, Nov. 25, 2007, at P11.          
 
5 See Pilar N. Ossorio, About Face: Forensic Genetic Testing for Race and Visible Traits, 34 J.L. MED. & ETHICS 
277, 278-279 (2006); Statement of the American Sociological Association, The Importance of Collecting Data and 
Doing Social Scientific Research on Race, American Sociological Association, available at <http:// 
www.asanet.org/governance/racestmt.html> (last visited Feb. 15, 2007); A. Smedley & B. D. Smedley, Race as 
Biology is Fiction, Racism as a Social Problem is Real, 60 AMERICAN PSYCHOLOGIST 16-25 (2005).  See also infra 
notes 13-19 and accompanying text.   
5are inconsistent with the scientific reality of human genetics.6 The fundamental argument is that 
genetics groups us differently, often dramatically so, and it is scientifically and socially 
misguided and contrary to ample U.S. law and policy, perhaps even illegal, to approach 
contemporary population genetics with methodologies that embrace these constructs.7 While 
the debate over race-based research has been of mixed opinion in the natural science and medical 
disciplines,8 there is a discernable majority opinion among law academics that most race-based 
research is wrong on multiple levels.9
6 See infra notes 63-98 and accompanying text. 
 
7 See generally id. 
8 Contrary science positions on race-based research were juxtaposed in the November 2004 issue of Nature 
Genetics. See M. Bamshad, et al., Deconstructing the Relationship Between Genetics and Race, 5 NATURE GEN.
598-609 (2004); Francis Collins, What We Do and Don't Know About 'Race,' 'Ethnicity,' Genetics and Health at the 
Dawn of the Genome Era, 36 NATURE GEN. SUPP. S13-S15 (2004); E. J. Parra, R. A. Kittles, M. D. Shriver, 
Implications of Correlation Between Skin Color and Genetic Ancestry for Biomedical Research, 36 NAT. GENET.
SUPP. S54-S60 (2004); J. L. Mountain, N. Risch, Assessing Genetic Contributions to Phenotypic Differences Among 
`Racial' and `Ethnic' Groups, 36 NAT GENET SUPP. S48-S53 (2004).  See also, P. Sankar, Mildred K. Cho, C. M. 
Condit, et al., Genetic Research and Health Disparities. 291 JAMA 2985-9 (2004); K. R. Merikangas, N. Risch, 
Genomic Priorities and Public Health, 302 SCIENCE 599-601 (2003);  E. G. Burchard, et al., The Importance of 
Race and Ethnic Background in Biomedical Research and Clinical Practice, 348 N. ENG. J. MED. 1170-71 (2003):  
R. S. Cooper, et al., Race and Genomics, 348 N. ENG. J.MED. 1166-67 (2003); N. A. Rosenberg, J. K. Pritchard, J. 
L. Weber, et al., Genetic Structure of Human Populations, 298 SCIENCE  2381-5 (2002); N. Risch, et al., 
Categorization of Humans in Biomedical Research: Genes, Race and Disease, 3 GENOME BIOLOGY 1-12 (2002): R. 
S. Schwartz, Racial Profiling in Medical Research, 344 N. ENG. J. MED. 1392-93 (2001); A. J. J. Wood, Racial 
Differences in the Response to Drugs--Pointers to Genetic Differences, 344 N. ENG. J.MED. 1393-96 (2001).  The 
debate has intensified.  See, e.g., Bibbins-Domingo, K., & Fernandez, ABiDil for Heart Failure in Black Patients: 
Implications of the U.S. Food and Drug Administration Approval, 146 ANN INTERN MED 52-56 (2007); Guthery, S. 
L., Salisbury, B. A., Pungliya, M. S., Stephens, J. C., & Bamshad, M, The Structure of Common Genetic Variation 
in United States Populations, 81 AM J HUM GENET 1221-1231 (2007); Hafler, D. A., Compston, A., Sawcer, S., 
Lander, E. S., Daly, M. J., De Jager, P. L., et al., Risk Alleles for Multiple Sclerosis Identified by a Genomewide 
Study, 357 N ENGL J MED. 851-862 (2007); Wu, Y.-R., Chen, C.-M., Chao, C.-Y., Ro, L.-S., Lyu, R.-K., Chang, K.-
H., et al., A Nonsynonymous SNP in Human Cytosolic Sialidase in a Small Asian Population Results in Reduced 
Enzyme Activity: Potential Link With Severe Adverse Reactions to Oseltamivir, 17 CELL RESEARCH 357–362 (2007); 
Neil Risch, Dissecting Racial and Ethnic Differences, 354 NEW ENG. J. MED. 408 (2006); M. Sinha, E. K. Larkin, R. 
C. Elston, S. Redline, Self-Reported Race and Genetic Admixture, 354 N ENGL J MED 421-2 (2006); Daar, A. S., & 
Singer, P. A, Pharmacogenetics and Geographical Ancestry: Implications for Drug Development and Global 
Health, 6 NAT REV GENET. 241-246 (2005); H. Tang, T. Quertermous, B. Rodriguez, et al., Genetic Structure, Self-
Identified Raceethnicity, and Confounding in Case-Control Association Studies, 76 AM J HUM GEN. 268-75 (2005); 
A. E. Shields, M. Fortun, E. M. Hammonds, et al., The Use of Race Variables in Genetic Studies of Complex Traits 
and the Goal of Reducing Health Disparities: a Transdisciplinary Perspective, 60 AM PSYCHOLOGY 77-103 (2005).  
Opponents argue that race lacks any reliable biological basis and, for genetics research to contribute meaningfully to 
science and medicine, links between genes and disease should be made directly—for example, through single 
nucleotide polymorphisms (“SNPs”) and other specific genetic characteristics associated with diseases and 
6This article proposes that responsible race-based genetics biomedical research—basic, 
clinical and epidemiological—is possible, and even desirable.  A primary premise for the 
argument is that the concepts of race and ethnicity, like genetic science,10 are neither innately 
good nor bad.  Contrary to the dominant path followed by law academics,11 which is to approach 
race-based research from anti-discrimination jurisprudence, this article approaches race-based 
 
responses to medications.   See generally M. Bamshad, Deconstructing, supra, at 509.  See also infra note 46 and 
accompanying text (SNPs addressed).  Proponents argue that race does have a genetic basis—that, at the very least, 
it influences lifestyle choices resulting in shared environmental exposures, and DNA links people to geographic 
continents-regions that correspond with their self-identified racial classifications.  See id. at 939-40. See, e.g., Race, 
Ethnicity, and Genetics Working Group, The Use of Racial, Ethnic, and Ancestral Categories in Human Genetics 
Research, 77 AM. J. HUM. GEN. 519-32 (2005); K Olden, SL White, Health-Related Disparities: Influence of 
Environmental Factors, 89 MED. CLIN. NORTH AM. 721-38 (2005); E. Gonzalez Burchard, L. N. Borrell, S. 
Choudhry, et al., Latino Populations: a Unique Opportunity for the Study of Race, Genetics, and Social 
Environment in Epidemiological Research, 95 AM J PUBLIC HEALTH 2161-8 (2005).  See also C. W. MILLS, THE
RACIAL CONTRACt (Ithaca, NY: Cornell University Press, 1997); P. KITCHER, IN MENDEL'S MIRROR:
PHILOSOPHICAL REFLECTIONS ON BIOLOGY 239-45 (2003).    
 
9 See, e.g., Jonathan Kahn, Race-Ing Patents/Patenting Race: An Emerging Political Geography of Political 
Geography in Biotechnology, 92 IOWA L. REV. 353 (2007); Erik Lillquist Charles A. Sullivan, Legal Regulations of 
the Use of Race in Medical Research, 34 J. L. MED. ETHICS 535-547 (2006);  Dorothy Roberts, Legal Constraints on 
the Use of Race and Ethnicity in Biomedical Research, 34 J. L. MED & ETHICS 526-534 (2006); Sharona Hoffman, 
“Racially-Tailored” Medicine Unraveled, 55 Am. U. L. Rev. 395-456 (2005); Erik Lillquist & Charles A. Sullivan, 
The Law and Genetics of Racial Profiling in Medicine, 39 Harv. Civ. Rts-Civ. Lib. L. Rev. 442 391-483 (2004); 
Jonathan Kahn, How a Drug Becomes 'Ethnic': Law, Commerce, and the Production of Racial Categories in 
Medicine, 4 YALE J. HEALTH POL. L. & ETHICS 1-46 (2004).  See also infra notes ___ and accompanying text.   It is 
important to note that the law literature includes contributions to the race-based genetics debate from authors whose 
primary disciplines are in medicine and natural science, and they tend to be more receptive to, and even supportive 
of, this research.  See, e.g., Jay N. Cohn, The Use of Race and Ethnicity in Medicine: Lessons From the African-
American Heart Failure Trial, 34 J.L. MED. & ETHICS 552 (2006); Raj Bhopal, Race and Ethnicity: Responsible Use 
from Epidemiological and Public Health Perspectives, 34 J. L. MED. & ETHICS 500 (2006), citing Raj Bhopal, Is 
Research Into Ethnicity and Health Racist, Unsound, or Important Science?, 314 BRIT. MED. J. 1751-56 (1997), and 
R. Bhopal, Ethnicity as a Variable in Epidemiological Research, 309 BRIT. MED. J. 327-28 (1994).  See also 
Margaret A. Winker, Race and Ethnicity in Medical Research: Requirements Meet Reality, 34 J.L. MED. & ETHICS 
520 (2006); Morris W. Foster, Analyzing the Use of Race and Ethnicity in Biomedical Research from Local 
Community Perspective, 34 J.L. MED. & ETHICS 508 (2006); Michael D. Ruel, Commentary, Using Race in Clinical 
Research to Develop Tailored Medications, 27 J. LEGAL MED. 225 (2006).   
 
10 Over the years, many have observed that the impact of genetic technology depends on how it is used.  For 
example, in the context of one of the two most fundamental healthcare essentials, food (the other being water), 
genetic technology can be "democratically managed to the benefit of the most needy or skewed to the advantage of 
specific groups that hold the vital political, economical and technological power."  Illenia M. Demenina, Note and 
Comment, Genetically Modified Foods in the International Arena: Trade labeling Controversy and the Importance 
of Informed Consumer Choice, 2 B.Y.U. Int’l. & Mngt. Rev. 311 (2006), citing Sara J. MacLaughlin, Food for the 
Twenty-First Century: An Analysis of Regulations for Genetically Engineered Food in the United States, Canada, 
and the European Union, 14 IND. INT’L & COMP. L. REV. 375, 405 (2003). 
 
11 See, e.g., Lillquist & Sullivan, Use of Race, supra note 9; Hoffman, Unraveled, supra note 9.  
 
7research with the goal of promoting thoughtful bioethics compliance and with the legal mindset 
of inclusion analogous to the goals of affirmative action.  This position is supported with 
arguments based in research pragmatism, genetic science, and applied bioethics—namely 
regulations to protect human subjects12 and the fundamental principals documented in the 
Declaration of Helsinki13 and the Belmont Report.14
The article begins with a discussion of the natural science context forming the 
background of the debate.  Part II presents an overview of contemporary genetics research and 
medicine with a focus on the increased appreciation of the subtleties and pervasiveness of 
environmental influences on human genetics, and the heightened importance of population 
genetics following completion of the map of the human genome.15 Part III summarizes the 
ongoing debate in the sciences, medicine, and law over race-based genetics research.  Part IV 
 
12 In the United States, human subjects in research are protected through the Common Rule, 45 C.F.R. § 46 (2005), 
and separate Food and Drug Administration regulations, 21 C.F.R. § 50.20 (2005).  See also Bonnie M. Lee, U.S. 
Food and Drug Administration, Comparison of FDA and HHS Human Subject Protection Regulations, 2000, 
available at http://www.fda.gov/oc/gcp/comparison.html (last visited July 27, 2007). 
 
13 World Medical Association, Declaration of Helsinki: Ethical Principles for Medical Research Involving Human 
Subjects (1964). The Declaration has been amended several times since 1964, including in 2002 and 2004.  For 
more information, visit the internet site of the World Medical Association, available at http://www.wma.net/e/ (last 
visited Aug.2, 2007). 
 
14 The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, at 
http://ohsr.od.nih.gov/mpa/belmont.php3 (last visited Aug. 4, 2007). 
 
15 The actual human genome map is available through the Encyclopedia of DNA Elements (“ENCODE”) Project, a 
public research consortium launched by the National Human Genome Research Institute (“NHGRI”), information 
about which is available at http://www.genome.gov/10005107 (last visited July 28, 2007), and related sites, 
including UCSC Genome Bioinformatics, available at http://genome.ucsc.edu/ (last visited Aug. 2, 2007).  Visit 
NHGRI, ENCODE Overview, available at http://www.genome.gov/10005107 (last visited May 4, 2007).  Professor 
Bartha Knoppers addresses the importance of population genetics as a means to make medical sense out of the map 
of the human genome in Biobanking: International Norms, 33 J. L. MED. & ETHICS 7, 7-12 (2005); Bartha Maria 
Knoppers, Overview of Law and Policy Challenges, 66 LA. L. REV. 21, 21-31 (2005).  For general discussion of 
genetic science and medicine in the aftermath of HGP, see generally JAMES D. WATSON, DNA: THE SECRET OF LIFE 
(Alfred A. Knopf ed., 2003); THE GENOMIC REVOLUTION: UNVEILING THE UNITY OF LIFE (Michael Yudell & Robert 
DeSalle eds., 2002) (concluding, "The knowledge gained [from HGP] could cure cancer, prevent heart disease, and 
feed millions. At the same time, its improper use can discriminate, stigmatize, and cheapen life through frivolous 
enhancement technologies."); Allen Guttmacher & Francis Collins, Welcome to the Genomic Era, 349 NEW ENG. J. 
MED. 996-98 (2004), available at www.nejm.org (last visited Aug. 3, 2007); Climbing the Helical Staircase: A 
Survey of Biotechnology, THE ECONOMIST, Mar. 29, 2003, at 1-24.  
8presents a hypothetical case study illustrating the scientific complications and potential group 
and social benefits of population genetics.  This case study was selected to the side of the issue 
of the race controversy intentionally with three primary objectives: to focus on population 
genetics in the context of ongoing biomedical science and explain science fundamentals; to 
emphasize that groups organized by genetic disease, often seen as a preferable alternative, may 
in fact be no more homogenous than groups organized by race and ethnicity, even less so, while 
still serving as a valuable research resource; and to demonstrate that responsible biobanking may 
be beneficial on multiple levels regardless of the group collection criteria.   The case study 
illustrates the pervasive disconnect between phenotype (physical characteristics) and genetics 
even in a group defined by a somewhat rare genetic disease; the bioethics benefits and 
pragmatism of working with any population on its own social and cultural terms; the potential 
control exercised by and benefits to the group under study; and the potential scientific and 
medical returns, which tend to transcend a  group under study given the youth and genetics 
sameness of the human species.  The overarching message is that responsible biobanking within 
any population enables research to move forward and may contribute tremendously to human 
health in sometimes very unpredictable ways.   
The focus of Part V shifts back to race and ethnicity and proposes that recognition of and 
responsiveness to social constructs of race and ethnicity promotes the fundamental principles of 
contemporary bioethics.  This argument rests heavily on the observations that, first, race and 
ethnicity are as real socially as genetics is scientifically.  Second, these concepts, albeit social 
and cultural constructs,16 have influenced, and in future generations will continue to influence, 
 
16 See supra note 1 and accompanying text. 
 
9how people perceive themselves, whom they marry, their lifestyles, and how others perceive and 
interact with them—in other words, myriad environmental and genetic influences.17
The article concludes that, while the dangers of exploitation and discrimination must be 
underscored,18 the concepts of race and ethnicity should be fully recognized and responded to in 
a receptive manner by the scientific communities.  In fact, the article proposes that applied 
bioethics and scientific pragmatism favor recognizing race and ethnicity19 as a preferred 
methodology for population genetics because this approach is most sensitive to self-
identification by study subjects, communication with individual members of groups under study, 
realization of individual consent, recognition and assessment of group impact, and the 
development and realization of group consent in contemporary population genetics.20 In 
addition, the article illustrates that “shoddy science” arguments against race-based genetics 
research are actually consistent with the goal of its advancement in a bioethics-sensitive manner, 
especially given the intensity of the surrounding debate and the critiquing environment that 
encompasses this research.  As explained in the article, in the event the critics are correct, the 
 
17 “Beliefs about race, and behaviors that construct race, can be derived and analyzed using research methods from 
history, law, anthropology, sociology and psychology.”  Ossorrio, About Face, supra note 2, at 278.  See generally 
Race, Ethnicity, and Genetics Working Group, The Use of Racial, Ethnic, and Ancestral Categories in Human 
Genetics Research, 77 AM. J. HUMAN GENETICS 519-32 (2005); KITCHER, supra note 8.  See infra notes 157-160 
and accompanying text.  Even Professors Lillquist and Sullivan, among the sharpest law academia critics of race-
based research, have acknowledged that “it has been relatively safe, at least in the United States, to assume that race 
correlated with ancestry, although even in the United States the admixture of races is significant.”  Lillquist & 
Sullivan, supra note 9, at 544.       
 
18 Troy Duster, Race and Reification in Science, 307 SCI. 1050, 1050 (2005); Hoffman, Unraveled, supra note 6, at 
420-27; Michael J. Malinowski, Choosing the Genetic Makeup of Our Children: Our Eugenics Past—Present, and 
Future?, 36 CONN. L. REV. 125, 172–97 (2003).   
 
19 It is important to note the distinctions and connections among race, ethnicity, and ancestry, which have been 
explained fully in both the science and law literature.  See, e.g., Race, Ethnicity, and Genetics Working Group, The 
Use of Race, Ethnic, and Ancestral Categories in Human Genetics Research, 77 AM. J. HUM. GEN. 519-32 (2005); 
Lillquist & Sullivan, Use of Race, supra note 6, at 536-537.  See generally KITCHER, supra note 8.    
 
20 See generally Henry Greely, Population Participation and Other Factors that Impact the Compilation and the 
Utility of Resulting Databases, 66 LA L. REV. 79 (2005).  See also Bartha Maria Knoppers, Biobanking: 
International Norms, 33 J. L. MED. & ETHICS 7, 10 (2005).  See infra notes 177-198 and accompanying text. 
10
advancement of race-based genetics will further establish the genetic fallacy of these groupings, 
create an opportunity for groups organized by race and ethnicity to participate in the genomics 
revolution on favorable terms as determined by them, and may result in genetic medicine 
applications that benefit the groups understudy directly and that transcend these groups and 
benefit the entire human species.  This research also would advance fields of science such as 
epigenetics: the study of heritable changes in gene function that occur without a change in DNA,
which some are referring to as the “other human genome.”21 Epigenetics is grounded in 
appreciation for the extent to which environment and lifestyle choices impact gene expression, 
for example, the environmental influences that often cause identical twins to become very 
different people as they progress through life.22 
II. Measuring the Genetic Reality of Race, Then and Now 
 The present natural science debate over race-based genetics research is the progeny of 
another started nearly half a century ago23—one deeply influenced by the experience of grossly 
commingling life science in genetics and social science in eugenics at the turn of the Twentieth 
Century through the era of Nazi Medicine,24 all in addition to the U.S. legacy of discrimination 
based upon race and ethnicity.25 A particular field of science has driven each era in the debate, 
 
21 See generally DAVID C. ALLIS, THOMAS JENUWEIN, & DANNY REINBERG, EPIGENETICS (2007); Adrian Bird, 
Perceptions of Epigenetics, NATURE, May 24, 2007, vol. 447, no. 7143 (May 24, 2007); JAMES A. GOODRICH,
BINDING AND KINETICS FOR MOLECULAR BIOLOGISTS (2007); ERIC H. DAVISON, THE REGULATORY GENOME: GENE 
REGULATORY NETWORKS IN DEVELOPMENT AND EVOLUTION (2006); Epigenetics, SCIENCE, Aug. 10, 2001 (Spec. 
Iss.); visit Epigenetics,  http://www.pbs.org/wgbh/nova/sciencenow/3411/02.html.
22 See generally supra note 21. 
 
23 See generally infra Part II.A. 
 
24 Malinowski, Choosing, supra note 18, at nn. 25-67 and accompanying text. 
 
25 See generally, Ian F. Haney Lopez, “A Nation of Minorities”: Race, Ethnicity, and Reactionary Colorblindness,
59 STAN. L. REV. 985 (2007); Daniel J. Sharfstein, Crossing the Color Line: Racial Migration and the One-Drop 
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which has been cumulative and has grown more complicated over time.  The intensity and 
richness of the present debate, including the genetic science community’s response to Dr. 
Watson’s recent comments,26 is the greatest assurance that race-based research and its outcomes 
will be scrutinized thoroughly—both scientifically and ethically.     
A. Genetic Anthropology and Evolutionary Biology 
 The original post-World War II discourse over race-based genetics inspired several fields, 
including genetic anthropology27 and molecular evolution,28 which emerged in the 1960s and 
grew significantly throughout the 1970s.29 By the 1980s, the debate had been largely quieted by 
an impressive body of scholarship that established persuasively that race is a social construct, not 
a genetic reality.  Much of this scholarship is attributable to: Luca Cavalli-Sforza from Stanford 
University, widely recognized as the father of genetic anthropology;30 Marcus Feldman, a 
Stanford colleague and collaborator of Professor Cavalli-Sforza, whose work centered on the 
 
Rule, 1600-1860, 91 MINN. L. REV. 592 (2007); KENNETH B. CLARK, DARK GHETTO: DILEMMAS OF SOCIAL POWER 
(1965). 
 
26 See supra notes 1-3 and accompanying text. 
 
27 See infra note 20. 
 
28 See infra note 22. 
 
29 This debate was a response to the jolt in understanding of human genetics following the discovery of the double 
helix structure of DNA by Dr. James Watson and Francis Crick in 1953.  See generally JAMES WATSON, THE 
DOUBLE HELIX (1968). 
 
30 Professor Cavalli-Sforza’s vast body of related scholarship before, during, and subsequent to the 1980s includes 
LUCA L. CAVALLI-SFORZA & W. BODMER, THE GENETICS OF HUMAN POPULATIONS (1999); LUCA L. CAVALLI-
SFORZA, P. MENOZZI, AND A. PIAZZA, THE HISTORY AND GEOGRAPHY OF HUMAN GENES (1994); Luca L Cavalli-
Sforza, The Human Genome Diversity Project: Past, Present and Future, 4 NAT REV GENET 333-40 (2005); Luca L. 
Cavalli-Sforza, Studying Diversity, 6 EMBO REP 713 (2005); Luca L. Cavalli-Sforza, Man and the Diversity of His 
Genome. An Extraordinary Phase in the History of Population Genetics, 46 PATHOL BIOL (PARIS) 98-102 (1998); 
Luca L. Cavalli-Sforza, The DNA Revolution in Population Genetics, 16 TRENDS GENET 60-5 (1998); Luca L. 
Cavalli-Sforza, P. Menozzi,  A. Piazza, Demic Expansions and Human Evolution, 259 SCIENCE 639-46 (1993). 
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genetic evolution of complex systems;31 and zoologist Richard Lewontin from Harvard 
University, who established the mathematical basis of population genetics and is often credited 
with founding the field of molecular evolution.32 These scientists demonstrated that there was 
greater genetic variation within the racial groups they studied than between them, meaning that 
grouping based upon genetic commonality crossed the racial lines they tested.  As stated by 
Professor Lewontin, “For the vast majority of human genetic variations, classical racial 
categories as defined by a combination of geography, skin color, nose and hair shape, and an 
occasional blood type or selected microsatellites make no useful prediction of genetic 
differences.”33 Consequently, during the last quarter of the last century, the natural science 
community, including the genetics community, largely abandoned race and ethnicity as 
biological categories. 
B. The Social Scientists 
 Then, during the 1990s, the social science community reinvigorated the debate.  The late 
Richard Herrnstein and Charles Murray published The Bell Curve, in which they attempted to 
measure the role intelligence plays in shaping social and economic differences between ethnic 
groups in America. 34 They claimed that intelligence is genetically inheritable in a predictable 
 
31 See, e.g., LUCA L. CAVALLI-SFORZA & MARCUS W. FELDMAN, CULTURAL TRANSMISSION AND EVOLUTION 
(1981); Luca L. Cavalli-Sforza & Marcus W. Feldman, The Application of Molecular Genetic Approaches to the 
Study of Human Evolution, 33 NAT GENET (SUPP.) 266-75 (2003). 
 
32 See RICHARD C. LEWONTIN, THE TRIPLE HELIX: GENE, ORGANISM, AND ENVIRONMENT (2000);  RICHARD C
LEWONTIN, BIOLOGY AS IDEOLOGY: THE DOCTRINE OF DNA (1993).  For a recent statement about race and genetics 
by Professor Lewontin, see Richard Lewontin, Confusions About Human Races, Apr. 20, 2005, posted on Is Race 
Real?, A Web Forum Organized by the Social Science Research Council, available at 
http://raceandgenomics.ssrc.org/Lewontin/ (last visited June 6, 2007). 
 
33 Confusions, supra note 32. 
 
34 See generally RICHARD HERNSTEIN & CHARLES MURRAY, THE BELL CURVE (1994). 
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manner, which they attempted to substantiate with research that relied on IQ scores.35 Hernstein 
and Murray concluded that African Americans are less intelligent than Whites based upon a 
fifteen to sixteen point differential on IQ tests:  
Despite the forbidding air that envelops the topic, ethnic differences in cognitive 
ability are neither surprising nor in doubt.  Large human populations differ in 
many ways, both cultural and biological.  It is not surprising that they might differ 
at least slightly in their cognitive characteristics.  That they do is confirmed by the 
data on ethnic differences in cognitive ability from around the world … The 
difference in test scores between African-Americans and European-Americans as 
measured in dozens of reputable studies has converged on approximately a one 
standard deviation difference for several decades.  Translated into centiles, this 
means that the average white person tests higher than about 84 percent of the 
population of blacks and that the average black person tests higher than about 16 
percent of the population of whites.36 
Critics questioned the objectivity of IQ tests and attributed economic disparities to less 
quantifiable data, such as social circumstances.37 
A year later, Michael Levin published Why Race Matters: Race Differences and What 
They Mean, in which he too claimed that African-Americans are less intelligent than whites,38
35 See generally id. 
36 Id. at 269. 
 
37 See, e.g., CLAUDE S. FISCHER ET AL., INEQUALITY BY DESIGN: CRACKING THE BELL CURVE MYTH (1996); THE 
BELL CURVE WARS: RACE, INTELLIGENCE, AND THE FUTURE OF America (Steven Fraser ed., 1995). 
 
38 See generally MICHAEL LEVIN, WHY RACE MATTERS: RACE DIFFERENCES AND WHAT THEY MEAN (1997). In 
Levin’s own words,  
[I]t always is assumed that Blacks are on average as intelligent as whites and as capable of passing 
any fair test in proportionate numbers. But there is now quite solid evidence that this assumption is 
not correct; the average black is significantly less intelligent than the average white. Therefore, the 
only adjustments in educational measures that will allow blacks their due number of successes 
amount to making course-work and tests easier and easier, and this is what has been going on for 
over thirty years. Conversely, if standards are going to be raised, cultural literacy reasserted and 
college education given its old depth and focus, the American policy will have to reconcile itself 
to an embarrassing failure rate for blacks. It has been amply confirmed over the last several 
decades that, on average, blacks are significantly less intelligent than whites. The black mean IQ is 
slightly more than one standard deviation below the white mean. In more familiar terms, that 
amounts to a difference of more than 15 points of IQ as measured by such standard tests as the 
Wechsler Adult Intelligence Scale. 
Id. at __. 
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and then went much further.  He concluded that African Americans are more aggressive, 
assertive, impulsive, and suffer from “an absence of conscience.”39 As with the work of 
Hernstein and Murray, Levin’s work was heavily criticized and entirely dismissed by many.40 
C.  The Surge in Population Genetics 
 The turn of the Millennium has brought a surge in race-based genetics research41 and 
genotype-phenotype connections associated with race.42 Additionally, considerable ancestry-
based research, though distinguishable,43 raises implications that are spilling into the race-
genetics controversy.44 The increase in race-based genetics research is attributable to completion 
 
39 Id. at 213, 322. 
 
40 See generally JOSEPH L. GRAVES, JR., THE EMPEROR'S NEW CLOTHES: BIOLOGICAL THEORIES OF RACE AT THE 
MILLENNIUM (2001).  According to Professor Graves, both The Bell Curve and Why Race Matters were funded in 
part by the Pioneer Fund, "The purpose of [which] was to demonstrate the genetic inferiority of blacks."  Id. at 154. 
 
41 See Neil Risch, Dissecting Racial and Ethnic Differences, 354 NEW ENG. J. MED. 408 (2006).  See generally 
supra note 5.  “There is a growing movement in medical genetics research and practice to develop, implement, and 
promote a model of race-based medicine.”  C. Condit & B. Bates, How Lay People Respond to Messages About 
Genetics, Health, and Race, 68 CLINICAL GENETICS 97 (2005). 
 
42 See, e.g., C. A. Haiman, D. O. Stram, L. R. Wilkens, et al., Ethnic and Racial Differences in the Smoking-Related 
Risk of Lung Cancer, 354 N ENGL J. MED 333-42 (2006) ; X. Zhu, A. Luke, R. S. Cooper, et al., Admixture Mapping 
for Hypertension Loci With Genome-Scan Markers, 37 NATURE GENETICS 177-81 (2005); Richard S. Cooper, et al., 
An International Comparative Study of Blood Pressure in Populations of European vs. African Descent, 3 BMC 
MED. 2 (2005); M. Nakajima, T. Yokoi, Interindividual Variability in Nicotine Metabolism: C-oxidation and 
Glucuronidation, 20 DRUG METAB PHARMACOKINET 227-35 (2005); G. E. Swan, N. L. Benowitz, C. N. Lessov, P. 
Jacob III, R. F. Tyndale, K. Wilhelmsen, Nicotine Metabolism: the Impact of CYP2A6 on Estimates of Additive 
Genetic Influence, 15 PHARMACOGENET GENOMICS 115-25 (2005); N. Kaniwa, K. Kurose, H. Jinno, et al., Racial 
Variability in Haplotype Frequencies of UGT1A1 and Glucuronidation Activity of a Novel Single Nucleotide 
Polymorphism 686C> T (P229L) Found in an African-American, 33 DRUG METAB DISPOS 458-65 (2005); F. 
Innocenti, S. D. Undevia, L. Iyer, et al., Genetic Variants in the UDP-Glucuronosyltransferase 1A1 Gene Predict 
the Risk of Severe Neutropenia of Irinotecan, 22 J CLIN ONCOL 1382-8 (2004); N. L. Benowitz, E. J. Perez-Stable, 
B. Herrera, P. Jacob III, Slower Metabolism and Reduced Intake of Nicotine from Cigarette Smoking in Chinese-
Americans, 94 J NATL CANCER INST 108-15 (2002); Neal L. Benowitz et al, Ethnic Differences in N-
Glucuronidation of Nicotine and Cotinine, 291 J. PHARMACOLOGY & EXPERIMENTAL THERAPEUTICS 1196 (1999); 
Daniel L. Dries et al., Racial Differences in the Outcome of Left Ventricular Dysfunction, 340 NEW ENG. J. MED.
609, 616 (1999); Michael J. Klag, et al, The Association of Skin Color With Blood Pressure in U.S. Blacks With Low 
Socioeconomic Status, 265 J. AM. MED. ASS’N 599 (1991).  For an insightful discussion of the clinical utility of race 
and ethnicity in medicine, see generally Cohn, supra note 9. 
 
43 For an excellent explanation of this distinction, see Ossorio, About Face, supra note 2, at 279-284. 
 
44 See Lillquist & Sullivan, Regulation, supra note 65, at 545-546.  Note that NIH’s National Human Genome 
Research Institute (“NHGRI”) has distinguished ancestry from race and ethnicity in its International HapMap 
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of the map of the human genome in 2001,45 the bioinformatics capabilities that enabled that 
accomplishment and which continue to expand by multiples, 46 and the broader understanding 
about human genetics that has followed. 47 Completion of the map of the human genome was 
both a remarkable accomplishment and humbling.  As former President Bill Clinton observed at 
the time of its announcement:    
We are here to celebrate the completion of the first survey of the entire human 
genome. Without a doubt, this is the most important, most wondrous map ever 
produced by humankind. 
 
More than 1,000 researchers across six nations have revealed nearly all 3 billion 
letters of our miraculous genetic code. I congratulate all of you on this stunning 
and humbling achievement. 
Today's announcement represents more than just an epic-making triumph of 
science and reason. After all, when Galileo discovered he could use the tools of 
mathematics and mechanics to understand the motion of celestial bodies, he felt, 
in the words of one eminent researcher, "that he had learned the language in 
which God created the universe." 
 
Project (“HMP”).  See The International Haplotype Mapping Project, available at http://www.hapmap.org/ (last 
visited July 12, 2007).  Nevertheless, HMP has raised many social, ethical and legal concerns about population 
genetics research that can be associated with race and ethnicity.  See generally Ellen Wright Clayton, Implications 
for Existing Law/Regulations, 66 LA. L. REV. (Special Issue) 125, 129 (2005); Pilar N. Ossorio, Race, Genetic 
Variation and the Haplotype Mapping Project, 66 LA. L. REV. (Special Issue) 131 (2005).  
 
45 See generally 291 SCIENCE 1145 (Feb. 16, 2001) (issue entitled "The Human Genome"); 409 NATURE 745 
(Feb. 15, 2001) (issue dedicated to the release of a draft map of the human genome). Timely information about the 
genomics revolution may be obtained from the National Human Genome Research Institute (NHGRI), available at 
http://www.nhgri.nih.gov (last visited May 24, 2007). 
 
46 See generally ESSENTIALS OF GENOMICS AND BIOINFORMATICS (C.W. Sensen ed., 2005); Robert Wells, 
Intellectual Property/Ownership Interests, 66 LA L. REV. 69, 70 (2006).   As explained previously,  
Even before completion of the map of the human genome, the biomedical research community 
began employing bioinformatics to undertake a challenge dimensions greater than the basic 
genome mapping: translating this rambling string of letters that constitute the genome map into 
medical meaning. Consider that even just single-letter changes may cause variance in 
responsiveness to pharmaceuticals and susceptibility to diseases.  The science community has 
been identifying these genetic idiosyncracies that appear in the human population with statistically 
significant regularity, known as SNPs, and compiling massive databases. 
Michael J. Malinowski, Technology Transfer in Biobanking: Credits, Debits, and Population Health Futures, 33 L. 
MED & ETHICS 54, 56 (2005). 
 
47 See generally PAUL MARTIN & MICHAEL MORRISON; REALIZING THE POTENTIAL OF GENOMIC MEDICINE (2006).  
Most notably, we came to understand that all human diversity is attributable to just 25,000 or less active genes.  See 
J. Michael McGinnis, Population Health and the Influence of Medical and Scientific Advances, 66 LA. L. REV. 9, 10 
(2005). 
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Today, we are learning the language in which God created life. 
Genome science will have a real impact on all our lives—and even more, on the 
lives of our children. It will revolutionize the diagnosis, prevention and treatment 
of most, if not all, human diseases.48
The map introduced perspective.  Rather than the 100,000 or so genes expected by most 
at the outset of HGP, a mere 25,000 or fewer genes are responsible for all human diversity.49 
“Yet, one need only ride the New York City subway a few stops or people watch in Times 
Square to witness just how diverse we are, especially for such a young species.  So, how do we 
resolve our genetic sameness with tangible human diversity?”50 Genes multitask exponentially 
more than anticipated.  Two unrelated human beings are separated by an estimated 3,000,000 
distinct DNA variants.51 With the map of the human genome in hand, those engaged in 
biopharmaceutical R&D and genetic medicine stepped into a universe of added complexity.   
Perspective has shifted: The scientific communities now have a significantly heightened 
appreciation for the dynamism of genetics, the intricacies of genetic expression, and the 
significance of interactions between genetics and environmental influences.52 This shift is 
reflected in the emergence of epigenetics, which centers on environmental influences on, not 
changes to, DNA that become heritable changes in gene function.53 
48 Visit http://www.genome.gov/10001356 (last visited May 16, 2007). 
49 McGinnis, Influence, supra note 38, at 10. 
 
50 Malinowski, Futures, supra note 46, at 56.  Henry T. Greely, Daniel P. Riordan, Nanibaa' A. Garrison, Joanna L. 
Mountain, Family Ties; The Use of DNA Offender Databases to Catch Offenders’ Kin, 34 J.L. MED. & Ethics 248, 
249 (2006). 
 
51 See SNP Consortium Ltd., Single Nucleotide Polymorphisms for Biomedical Research, available at 
http://snp.cshl.org (last visited May 12, 2007). See also L. Brooks and M. Guyer, National Human Genome 
Research Institute (HGRI), Resource for Studying Human Genetic Variation (March 1998), available at 
www.georgetown.edu/research/nrcbl/nbac/transcripts/mar98/hbmr_spkrs.htm (last visited Feb. 18, 2005). 
 
52 Cf. Richard S. Cooper & Bruce M. Psaty, Genomics and Medicine: Distraction, Incremental Progress, or the 
Dawn of a New Age?, 138 ANNALS INTERNAL MED. 576 (2003). 
 
53 See supra notes 21-22 and accompanying text. 
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As overwhelming as this shift in scale is, bioinformatics,54 the same technology that 
enabled completion of the map of the human genome is enabling scientists to make medical 
sense of it.  Rather than working only at the gene or even protein level, scientists are reaching 
down further to study variations in single nucleotide bases and their impact on phenotype 
(physical characteristics), which are known as single nucleotide polymorphisms (“SNPs”).55
Single letter variants can be subtle—for example, a trigger that causes a gene to not make a 
needed protein that, through an intricate pathway of interactions, results in nonresponsiveness or 
over-responsiveness to a particular pharmaceutical.  They also can be extreme, such as the 
deviation of one nucleotide that triggers Tay Sachs and takes a child’s life.56 Approximately two 
million of these subtle genetic variations with medical meaning have been identified—most a 
byproduct of the ongoing expenditure of tens of billions of dollars annually on 
biopharmaceutical research and development (“R&D”).57 Clusters of these variations inherited 
together are referred to as haplotypes.58
54 Bioinformatics is the combination of biology and information technology.  See generally, ESSENTIALS, supra note 
46; Wells, Ownership, supra note 46.  
55 SNPs are individual sites of genomic variation that occur with a frequency of at least 1% in the human population.  
See The International SNP Map Working Group, A Map of Human Genome Sequence Variation Containing 1.42 
million Single Nucleotide Polymorphisms, 409 NATURE 928-933 (2001).  For information about SNPs, visit the site 
of The SNP Consortium Ltd., supra note 44.  See generally Helen Berman & Rochelle Dreyfuss, Reflections on the 
Science and Law of Structural Biology, Genomics, and Drug Development, 53 UCLA L. REV. 871, 882-883 (2006). 
56 Tay-Sachs is caused by a recessive genetic allele, a genetic variation on chromosome 15.  For information, visit 
the Mayo Clinic internet site at http://www.mayoclinic.org/tay-sachs-disease/genetesting.html.  More information is 
available via the National Tay-Sachs and Allied Disease Association, available at http://www.ntsad.org (last visited 
May 16, 2007). 
 
57 Some of these commercial entities have joined a collaboration, The SNPs Consortium Ltd., supra note 44, to put 
SNPs into the public domain.   This effort is complemented by another consortium, the Wellcome Trust, which has a 
focus on structural genomics.  See Wellcome Trust, Structural Genomics Consortium, http:// 
www.wellcome.ac.uk/doc_WTD003502.html (last visited Oct. 31, 2005).  For information about biopharmaceutical 
investment in drug research and development, visit the sites of the U.S. pharmaceutical trade organization, 
Pharmaceutical Researchers and Manufacturers of American, www.phrma.org, and the U.S. biotechnology trade 
organization, the Biotechnology Industry Organization, www.bio.org (last visited June 4, 2007). 
 
58 See generally International HapMap Project, What is the HapMap?, http:// 
www.hapmap.org/whatishapmap.html.en (last visited Jan. 22, 2007). 
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Today’s quest to find medical meaning in the genome has raised insatiable demand for 
human biological samples and accompanying medical information.59 Appreciation for the scope 
of the universe of human genetic subtleties made discernable by the map of the human genome 
has expanded the scale of much genetics research from the study of families and disease groups 
to the study of entire populations.60
III. The Ongoing Debate Over Race-Based Research  
Though the genetics science community and its research is at the center of the ongoing 
debate over race-based research, the social science and law communities also are actively 
engaged—making the present debate full-bodied, interdisciplinary, sophisticated and 
challenging.61 As Professor Wolf has observed, “A number of conflicting proposals have been 
offered, some to discipline and improve the use of racial and ethnic categories, and some to 
eliminate such categories.  This is a debate affecting researchers, funders, journal editors, 
research participants, and the broader community.”62 
A. Opponents 
Those in the scientific and medical communities opposed to research based on race and 
ethnicity emphasize that these groupings are inconsistent with the scientific reality of human 
 
59 See Paula W. Yoon, Risk Prediction for Common Diseases, 66 LA L. REV. 33, 40 (2005). 
 
60 See generally Symposium: Regulation of Biobanks, 33 J. L. MED. & ETHICS 1-188 (Mark Rothstein & Bartha 
Knoppers eds., 2005); Populations and Genetics: Legal and Socio-Ethical Perspectives (Ed. Bartha Maria Knoppers, 
2003); Lorraine Sheremeta & Bartha Maria Knoppers, Beyond the Rhetoric: Population Genetics and Benefit-
Sharing, 11 HEALTH L.J. 89, 90 (2003) (listing privacy as one of many concerns raised in present DNA testing). 
 
61 Professor Troy Duster, a sociologist, is an active participant.  See infra note 58-59.  Among law academics, 
Professors Sharona Hoffman, Eric Lillquist, Charles Sullivan, and Jonathan Kahn entered the debate early and have 
been fully engaged, and Professor Susan Wolf hosted a major symposium in the fall of 2006 which generated an 
issue of the Journal of Law, Medicine and Ethics dedicated to the topic.  See supra note 9. 
 
62 Wolf, Debating Use, supra note 51, at 483.  
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genetics.63 They draw from the ample body of literature by Professors Cavalli-Sforza, Lewontin 
and their contemporaries, and also reference recent findings which bolster the argument that race 
and ethnicity are more social constructs than genetic realities.64 Opponents assert that a 
preferred methodology for population genetics is research centered on diseases or at least 
specific and more reliable genetic particulars.65 They argue this approach will help avoid 
wasting resources, forcing outcomes, and chancing the affirmation of racial and ethnic groupings 
and social stereotypes.  According to bioethicist and Ph.D. scientist Mildred Cho, the race and 
ethnicity categories are unworkable: “Because social perceptions of the meaning of race and 
ethnicity are extremely fluid, basing research findings on these categories or applying scientific 
findings based on perceived race or ethnicity is fraught with problems. Thus, attempts to “`better 
define [the racial and ethnic] structure [of drug response]’ will be futile.”66 
Sociologist Troy Duster and many other opponents raise concerns about biologic 
determinism, meaning that genetic protocols crafted around race and ethnicity will become self-
fulfilling prophecies.  They emphasize the genetic commonality in any group due to the youth of 
 
63 See, e.g., M. V. Osier, A.J. Pakstis, H. Soodyall, D. Comas, D. Goldman, K. Odunsi, F. Okonofua, J. Parnas, L. 
Schulz, J. Bertranpetit, B. Bonne-Tamir, R.-B. Lu, J.R. Kidd, and K.K. Kidd, A global Perspective on Genetic 
Variation at the ADH Genes Reveals Unusual Patterns of Linkage Disequilibrium and Diversity, 71 AM. J. HUM.
GEN. 84, 84-99 (2002); N.A. Rosenberg, J.K. Pritchard, J.L. Weber, H.M. Cann, K.K. Kidd, L.A. Zhivotovsky, & 
M.W. Feldman, Genetic Structure of Human Populations, 298 SCIENCE 2381-2385 (2002). J.R. Kidd, A.J. Pakstis, 
H. Zhao, R.-B. Lu, F.E. Okonofua, A. Odunsi, E. Grigorenko, B. Bonne-Tamir, J. Friedlaender, L.O. Schulz, J. 
Parnas, & K.K. Kidd, Haplotypes qnd Linkage Disequilibrium at the Phenylalanine Hydroxylase Locus (PAH) in a 
Global Representation of Populations, 66 AM. J. HUM. GEN. 1882-1899 (2000). 
64 See generally Ossorio, About Face, supra note 2; Ossorio, Genetic Variation, supra note 37. 
 
65 See generally Ossorio, About Face, supra note 2; Gegg Bloche, Market Incentives and Regulatory Constraints: 
Racial and Ethnic Categories in Pharmaceutical Research, 34 J. L., Med. & Ethics 555-558 (2006); Raj Bhopal & 
L. Donaldson, White, European, Western, Caucasian, or What?: Inappropriate Labeling in Research on Race, 
Ethnicity, and Health, 88 AM. J. OF PUB. H. 88, 1303-07 (1998); Foster, Analyzing Race, supra note 6; Margaret A. 
Winker, Race and Ethnicity in Medical Research: Requirements Meet Reality, 34 J. L. MED. & ETHICS 520 (2006).  
 
66 Mildred K. Cho, Racial and Ethnic Categories in Biomedical Research: There is No Baby in the Bathwater, 34 
J.L. MED. & ETHICS 497, 499 (2006), quoting Cohn, supra note 9. 
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the human species and its overwhelming genetic sameness.67 Professor Duster also addresses the 
broader social implications of underscoring lines traditionally drawn around groups based upon 
race and ethnicity through genetics research protocols that suggest their validity.  He warns that 
singling out these groups further affirms prejudices and increases their vulnerability to 
discrimination, exploitation, and health inequality.68 According to Professor Duster, 69 the 
scientific community has shifted from “genetic sameness” as the mantra for mapping the human 
genome to a mantra of “genetic differentiation” through ongoing efforts to make medical sense 
out of the genome map, including population genetics,70 pharmacogenomics,71 and identification 
of SNPs.72 
A number of law academics have entered the debate and have argued against the 
perpetuation of race in the biomedical context with cautions about the weighty social and legal 
implications involved.73 In fact, there is a discernible majority opinion among law academics 
 
67 See generally Troy Duster, Lessons from History: Why Race and Ethnicity Have Played a Major Role in 
Biomedical Research, 34 J.L. MED. & ETHICS 487 (2006); Prof. Troy Duster, Dinner Presentation, "The 
Globalization of Pharmaceutical Development: Race, Markets and Ethics" (Mar. 16, 2006, Santa Clara College of 
Law) (addressing the "shift from genetic sameness to individuality" pre- and post-HGP); Troy Duster, Race and 
Reification in Science, 307 SCI. 1050, 1050 (2005); Risch, Dissecting, supra note 8. 
 
68 Duster, Dinner Presentation, supra note 67.  See generally Duster, Reification, supra note 67; Duster, Lessons,
supra note 67.  Sociologist Rose Brewer recently raised many similar concerns.  See generally Rose M. Brewer, 
Thinking Critically About Race and Genetics, 34 J.L. MED. & ETHICS 513 (2006). 
 
69 Duster, Dinner Presentation, supra note 67. 
 
70 See supra notes 12, 32-50 and accompanying text. 
 
71 Complementary fields are pharmacogenomics, which is research centered on the expression of alleles shared by 
groups, and pharmacogenetics, the tailoring of health care and biopharmaceuticals to individual genetic profiles. See 
generally Michael J. Malinowski, Law, Policy, and Market Implications of Genetic Profiling in Drug Development,
2 H. J. OF HEALTH LAW & POL'Y 31-63, 31-43 (2003); L. Noah, The Coming Pharmacogneomics Revolution: 
Tailoring Drugs to Fit Patients' Genetic Profiles, 43 JURIMETRICS 1, 4-11 (2002). 
 
72 See supra notes 45-48 and accompanying text. 
 
73 See supra note 9 and accompanying text.   
 
21
that race-based genomics research is undesirable on multiple levels and perhaps even illegal.74
The literature includes articles by Professors Erik Lillquist and Charles Sullivan,75 Professor 
Sharona Hoffman,76 Professor Jonathon Kahn,77 and a University of Minnesota symposium 
chaired by Professor Wolf which includes an article by Professor Dorothy Roberts.78
Proposals have been made to distinguish basic, clinical, epidemiological, and other forms 
of research, and to introduce legal restraints on the use of race and ethnicity in a manner tailored 
to each research specialty.79 The general consensus among law opponents is that use of race and 
ethnicity in biomedical research always warrants caution and legal restraints, but there is a 
continuum: use of race in clinical research is least acceptable; use in epidemiological research, 
such as research on the correlation between race and health disparities, is most acceptable; and 
other types of research place between the two.80 Also, the general consensus is that the use of 
race in research and medicine runs contrary to U.S. law and policy that broadly proscribes it.  
Professors Lillquist and Sullivan conclude that the use of race in research and medicine should 
be severely circumscribed, if not prohibited almost entirely.81 Their proposed standard for using 
 
74 See id. 
75 See generally Lillquist & Sullivan, Regulations, supra note 9.  See also Lillquist & Sullivan, Racial Profiling, 
supra note 9, at 442. 
 
76 See Hoffman, Unraveled, supra note 9, at 395-456. 
 
77 See generally Kahn, Racing Patent, supra note 9; Kahn, Racial Categories, supra note 9, at 25. 
 
78 See generally Symposium, The Responsible Use of Racial and Ethnic Categories in Biomedical Research: Where 
Do We Go From Here?, 34 J.L. MED. & ETHICS 483 (fall 2006) (published outcomes of live symposium at Univ. of 
Minnesota); Roberts, Legal Constraints, supra note 6.  Many of the contributors to this symposium were trained in 
disciplines outside of law and approached the topic accordingly.  See generally id. For citations to the other 
symposium pieces, see supra note 0. 
 
79 See Lillquist & Sullivan, Regulation, supra note 9, at 543-547.   
 
80 Id. at 546. 
 
81 See generally Lillquist & Sullivan, Racial Profiling, supra note 9. 
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race in medical treatment is extremely restrictive.  They would require a scientific basis to 
establish not simply that use of race is helpful in diagnosis and treatment, but that it is the best 
known method at the time.82 Professor Hoffman declares that “‘race-based’ medicine is an 
inappropriate and perilous approach”83 and proposes regulatory reforms to heavily restrain, if not 
entirely eliminate, both race-based research and medicine.84 She proposes “attributes-based” 
identification as a race-neutral alternative.85 
82 Id. at 442.  
 
83 Hoffman, Unraveled, supra note 9, at 397. 
 
84 See generally id.  
 
85 As Professor Hoffman explained,  
[T]o the extent that a group-oriented approach is pursued, it should be attribute-based rather than 
`race-based,’ and scientists should invest considerable effort in accurately identifying the attribute 
or attributes at issue. . . . The variables that might be relevant for a particular procedure or therapy 
could include socioeconomic status, diet, exercise, stress level, exposure to environmental toxins, 
cultural and religious barriers to treatment compliance, specific genetic alterations that influence 
disease course or disease vulnerability, and other factors. 
Id. at 398.   
 NIH is considering adoption of Professor Hoffman’s attributes-based identification, at least according to a 
NIH representative during the question and answer session following Professor Hoffman’s presentation at the 30th 
Annual Health Law Teacher’s Conference in June 2006.   Session on Race-Based Research, 30th Annual Health Law 
Teachers Conference, University of Maryland School of Law, June 1-3, 2006 (sponsored by the American Society 
of Law, Medicine, and Ethics; materials on file with author, including list of attendees).  NIH regulations expressly 
require inclusion of minority groups in clinical research. NIH Policy on Reporting Race and Ethnicity Data: Subjects 
in Clinical Research, August 8, 2001, available at <http:// grants1.nih.gov/grants/guide/notice-files/NOT-OD-01-
053.html (last visited June 12, 2006); U.S. Department of Health and Human Services, "Policy Statement on 
Inclusion of Race and Ethnicity in HHS Data Collection Activities" (1997), available at 
http://aspe.os.dhhs.gov/datacncl/racerpt/appendg.htm (last visited June 28, 2006).  Under these rules, applicants for 
grant funding must measure and report the race and ethnic composition of their intended study population and 
provide a rationale for subject selection, in part to ensure inclusion of non-White populations traditionally 
understudied.  National Institutes of Health, "Policy and Guidelines on the Inclusion of Women and Minorities as 
Subjects in Clinical Research," last modified Oct. 11, 2001, available at http:// 
grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm (last visited Mar. 10, 2007).   
 Adoption of the attributes-based approach would introduce administrative and compliance complexity and 
inconsistency in federal policy, as recognized by the Office of Management and Budget (“OMB”), which has 
refused to stray from race and ethnicity classifications for these very reasons.  Under OMB Directive 15, race and 
ethnic classifications are used for administrative practicality, as when conducting the national census. Statistical 
Directive No. 15: Race and Ethnic Standards for Federal Agencies and Administrative Reporting, 43 Fed. Reg. 
19,269-70 (May 4, 1978) [hereinafter Statistical Directive 15].  The classifications also are used by government 
entities in a range of programs that require consideration of race with the objective of bringing about inclusion 
where there has been a legacy of the opposite, including in biomedical research.  See, e.g., CDC, "Racial and Ethnic 
Approaches to Community Health: Goals for 2010," available at http://www.cdc.gov/reach2010/goals.htm (last 
visited July 12, 2007).   In other words, race and ethnicity are recognized to include and counter a legacy of 
exclusion and discrimination.  Even Professor Dorothy Roberts who opposes the use of race and ethnicity in 
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Collectively, law academics generally approach race-based research from U.S. 
jurisprudence and public policy against discrimination and associated social and ethical 
concerns.86 Their analysis of potential legal constraints on race-centered research begins with 
restrictions on intentional disparate treatment based on race by government entities under the 
Equal Protection Clause of the Fourteenth Amendment and the Due Process Clause of the Fifth 
Amendment.87 They emphasize that government use of racial classifications triggers strict 
scrutiny, but recognize that government actions, including programs thoughtfully crafted to 
promote affirmative action, survive such scrutiny where there is a compelling government 
interest and the use of race is narrowly tailored to promote that interest.88 They generally 
concede that, under established jurisprudence, government sponsorship of responsible race-based 
genetics research is likely to survive such challenges, though the present Court recently 
 
biomedical research supports their use to study and eliminate disparities in access to health care and medical 
treatment.  See Roberts, Legal Constraints, supra note 9, at 532-533. 
 
86 See, e.g. , Hoffman, Unraveled, supra note 9; Lillquist & Sullivan, Regulation, supra note 9. 
 
87 See generally Grutter v. Bollinger, 539 U.S. 306 (2003) (holding that the Univ. of Mich. Law School 
has a compelling interest in attaining a diverse student body and that its affirmative action 
admissions program was narrowly tailored to serve that compelling interest).  Presently there is 
some uncertainty regarding permissible government action in the context of race integration, for the 
Supreme Court revisited the 1954 Brown v. Board decision in cases heard December 2006, Parents 
Involved in Community Schools v. Seattle School District No. 1, 551 U.S. __ , 127 S.Ct. 2738, 75 USLW 
4577, 220 Ed. Law Rep. 84 (NO. 05-908, 05-915) (2007), and Meredith v. Jefferson County Board of Education,
127 S.Ct. 575 (Mem), 166 L.Ed.2d 407, 75 USLW 3247 (NO. 05-915) (2007).  See Adam Liptak, Brown v. 
Board of Education, Second Round, N.Y. TIMES, Dec. 10, 2006, at 3.  The Court considered whether 
school systems in Seattle, Washington, and Louisville, Kentucky, could take account of the races of 
students to achieve racial balance even though some students might be denied access to schools of 
choice due to race balance considerations.  See id. The Supreme Court concluded that “The school 
districts have not carried their heavy burden of showing that the interest they seek to achieve [, namely racial 
diversification,] justifies the extreme means they have chosen—discriminating among individual students based 
on race by relying upon racial classifications in making school assignments.”  Seattle, supra, at Slip. Op. para. 2, 
p. 2. 
88 See Grutter, 539 U.S. at 306.  
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questioned the Seattle and Kansas City school diversity policies and subjected them to further 
inquiry. 89 
Professors Hoffman, Lillquist, and Sullivan also look to statutory schemes that expand 
protection against racial discrimination—namely section 1981,90 Title VI,91 and Title II of the 
Civil Rights Act of 1964. 92 However, again, they concede the limited applicability of these 
provisions to race-based research.  First, as they address, while section 1981 reaches beyond 
government actions to contracts between private individuals, its prohibition on discrimination in 
contracts is limited to intentional disparate treatment.93 The reach of Title II is limited to 
discrimination or segregation in places of public accommodation, and courts have limited the 
reach of Title VII in the medical context.94 Although Title VII prohibits race discrimination in 
federally funded programs,95 courts have held that doctors receiving Medicare funding are not 
“programs” within the meaning of the statute.96 The case holdings suggest that medical research 
also would be beyond the statute’s reach.  Moreover, although Title VII allows private causes of 
 
89 See Seattle School District No. 1, 551 U.S. at __, and supra note 77.  Professors Lillquist and Sullivan have 
recognized that “The legal constraints on the use of race in research are more limited than might be expected given 
the strong ethical consensus against harmful use of racial categories.  The three major sources of federal regulation, 
the Equal Protection Clause and two federal statutory schemes, together leave large areas untouched.”  Lillquist & 
Sullivan, Legal Regulation, supra note 6, at 540.  Presumably the Supreme Court’s Seattle decision underscores this 
observation..   
 
90 42 U.S.C. § 1981 (2000). 
 
91 42 U.S.C. § 2000d (2000). 
 
92 42 U.S.C. § 2000a (2000). 
 
93 See Sullivan & Lillquist, Legal Regulation, supra note 9, at 540. 
 
94 See Hoffman, Unraveled, supra note 9, at 429-430. 
 
95 Title VII has been interpreted to prohibit both disparate treatment and disparate impact discrimination.  See 
Hoffman, Unraveled, supra note 6, at 441-442.  
 
96 See, e.g., Vuciecevic v. MacNeal Mem'l Hosp., 572 F. Supp. 1424, 1430 (N.D. Ill. 1983).  See generally Lillquist 
& Sullivan,  Racial Profiling, supra note 6, at 445.  In 1966, the Health, Education and Welfare Department decided 
to exempt physician Medicare participants from Title VII compliance.  See id. 
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action for intentional discrimination, only the federal government can challenge policies on the 
basis of disparate impact.97 Professors Lillquist and Sullivan also acknowledge that government 
restraints on private undertakings are limited by commercial free speech.98 
B. Proponents 
Contemporary biomedical research encompasses numerous methodologies centered on 
the study of populations, with the size of study groups varying from local communities to cross 
sections of the global human population.99 Those in the science and medical communities who 
support race-based research generally accept that grouping the human species on a universal 
level according to the greatest genetic common denominators would likely cut through our 
socially drawn race and ethnicity lines.100 The research of Professors Cavalli-Svorza, Lewontin, 
and their contemporaries is impressive and persuasive.101 However, proponents of race-based 
genetics research also are receptive to the notion that clusters of genetic commonalities, acquired 
through ancestry or shared environmental exposures (defined to fully encompass social 
influences), may be more prevalent in racial and ethnic groups than in the general population.102 
In other words, they work with the premise that (a) comprehensive human species challenges to 
the genetic reality of race and (b) the utility of race and ethnicity in population genetics are not 
 
97 Lillquist & Sullivan, Racial Profiling, supra note 9, at 447-448; Hoffman, Unraveled, supra note 9, at 441-442.  
 
98 See Lillquist & Sullivan, Racial Profiling, supra note 9, at 448-450.  See generally Wash. Legal Found. v. 
Henney, 202 F.3d 331 (D.C. Cir. 2000) (declaring the marketing of pharmaceutical products commercial free speech 
and limiting restrictions). 
 
99 Foster, Analyzing Race, supra note 9, at 508. 
 
100 The research and scholarship of Professors Cavalli-Sforza, Feldman, and Lewontin remain persuasive on this 
point.  See supra notes 30-33 and accompanying text.  
 
101 See id.  
102 See generally Cohn, Lessons, supra note 9; Bhopal, Responsible Use, supra note 9; Risch, Dissecting, supra note 
8.
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necessarily mutually exclusive.  Rather, they perceive them as distinguished by scope and 
complementary—along the lines of the use of micro- and macroeconomics by economists.103 
Supporters assert that, at least in some instances, research centered on racial and ethnic 
groupings has the potential to be a population extension of classic family pedigree studies in 
which research is conducted on a scale necessary to address the genetic intricacies we more fully 
discern and appreciate post completion of the human genome map. 104 A crisp illustration is an 
ongoing multiple sclerosis (MS) study carried out by the University of California at San 
Francisco and Harvard University under the International Multiple Sclerosis Genetic Consortium 
to identify genetic variants that account for the difference in the risk of developing MS between 
Africans and Europeans.105 The scientists are scanning DNA from African American MS 
patients for regions that have an unusually high proportion of European or African ancestry.106 
Their hypothesis is that, as the occurrence of MS is much higher in people of European ancestry, 
African Americans with MS have inherited a higher than average proportion of European 
 
103 The basic distinction is that microeconomics is about how markets operate while macroeconomics is about how 
economies function.  See generally SILK ET AL., MAKING CAPITALISM WORK 175 (1996); DOUGLASS C. NORTH,
ECONOMIC PERFORMANCE THROUGH TIME, PRIZE LECTURE IN ECONOMIC SCIENCE IN MEMORY OF ALFRED NOBEL 
(Dec. 9, 1993); PETER HOWITT, MACROECONOMICS: RELATIONS WITH MICROECONOMICS, IN 3 THE NEW PALGRAVE:
A DICTIONARY OF ECONOMICS 273-75 (John Eatwell et al. eds., 1989) (outlining the disjunction between micro and 
macro economics). 
 
104 Cf. Bhopal, Responsible Use, supra note 9, at 500.   
 
105 Daar & Singer, Geographical Ancestry, supra note 8 (editorial surveys ongoing pharmacogenetics research 
projects and identifies the potential benefits of this research for developing economies).   
 
106 This project is using 'admixture mapping', a type of haplotype association mapping.  See David Reich, Nick 
Patterson, et al., Letters, A Whole-Genome Admixture Scan Finds a Candidate Locus for Multiple Sclerosis 
Susceptibility, 37 NATURE 1113, 1113-1118 (Oct. 2005). For explanation and discussion of haplotype mapping, see 
supra note 58 and infra notes 110-118 and accompanying text. 
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chromosomal regions.107 The first part of this study already has brought science closer to 
interesting candidate genes.108 
Additional research results substantiate the scientific merit of this methodology:  Race 
and ethnicity-based genetics research is bestowing medical benefits to groups under study.  A 
notable example is identification of the genetic causes of adverse drug reactions (“ADRs”) to 
some commonly prescribed medications disproportionately prevalent in patients of South Asian 
descent, not a common focus group in biopharmaceutical research and development.  The use of 
oseltamivir, commonly known as Tamiflu and widely stockpiled for use in a possible avian 
influenza pandemic, has been associated with neuropsychiatric disorders and severe skin 
reactions primarily in patients of Japanese origin.109 ADRs from Tamiflu eventually were linked 
to a genetic aberration present in a small percentage of persons with Japanese origin.110 
Asian populations also have experienced a disproportionately high ADR incident rate—
ten percent—with rosuvastatin (commonly named Crestor), a routinely prescribed statin 
inhibitor.  The side-effects of muscular myopathy and rhabdomyolysis were observed during the 
Phase IV (post marketing) clinical testing period. The severity of these ADRs prompted a drug 
 
107 Daar & Singer, Pharmacogenetics, supra note 8, at 242. 
 
108 See generally Reich, et al., Whole-Genome Admixture, supra note 106. 
 
109 See generally Li, et al, Nonsynonymous SNP, supra note 8. 
 
110 This allele (genetic variation) is a nonsynonymous SNP (single nucleotide polymorphism) near the region of 
DNA coding for the enzymatic active site of human cytosolic sialidase, a homologue of virus neuraminidase that is 
the target of oseltamivir. This SNP, not observed in persons of European and African American descent, occurs in 
9.29 percent of Asian populations. ADRs to oseltamivir in Asian populations have been associated with the 
tendency of this SNP to reduce sialidase activity (Li et al., 2007).  The governing theory is that its presence increases 
the unintended binding affinity of human sialidase to oseltamivir carboxylate, the active form of oseltamivir, thus 
reducing sialidase activity. In addition, this SNP itself results in an enzyme with an intrinsically lower sialidase 
activity.  Id. 
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advisory memorandum from the FDA that specifically regulated the dosage of Crestor for 
persons of Asian descent.111 
These and other ADRs in populations associated with racial classifications have inspired 
several countries with Asian populations, populations not traditionally a study focus for 
biopharmaceutical R&D based in the U.S. and Europe, to unite and form The Pacific Pan-Asian 
SNP Initiative (“Pan-Asian Initiative”).112 The Initiative, hosted by the Genome Institute of 
Singapore, has brought scientists together to research the breadth of genetic diversity and the 
extent of genetic similarity within Asian populations.113 This information will form the basis for 
future studies in genomic medicine focused on Asian populations. Data from the Pan-Asian 
study will provide a platform for researchers in Asia to study why some populations seem 
predisposed to certain diseases, do not respond to certain drugs, or experience adverse drug 
reactions.114 Participating countries with complementary population genetics programs of their 
own include Japan,115 Taiwan,116 and China.117 
111 FDA Public Health Advisory on Crestor (rosuvastatin) (2005). 
 
112 See generally Daar & Singer, supra note 8. 
 
113 See id. 
114 See id. 
115 Japan begain the BioBank Japan Project in 2003 with the goal of collecting DNA, serum samples, and clinical 
information from 300,000 patients.  Triendl, R. Japan Launches Controversial Biobank Project, 9 NAT MED. 982 
(2003).  Biobank Japan is focused on elucidation of ADRs associated with oncological chemotherapy.  The overall 
goal of the BioBank Japan Project is to achieve personalized patient dosing capabilities to maximize positive 
responsiveness and avoid ADRs,  See generally Y. Nakamura, The BioBank Japan Project, 5 CLIN. ADV’S IN 
HEMATOLOGY & ONCOLOGY 696-697 (2007). 
 
116 The Taiwan Biobank was inspired by identification of hereditary and external risk factors unique to the 
Taiwanese.  See generally Wu, Y.-R., Chen, C.-M., Chao, C.-Y., Ro, L.-S., Lyu, R.-K., Chang, K.-H., et al., 
Glucocerebrosidase Gene Mutation is a Risk Factor for Early Onset of Parkinson Disease Among Taiwanese, 78 J. 
NEUROL NEUROSURG PSYCHIATRY 977-979 (2007).  The purpose of Taiwan Biobank is to investigate the gene 
factors behind common chronic diseases in Taiwan, such as cancer, high blood pressure, and diabetes, and the 
interactions of genetic and external risk factors.  See id. Early findings include identification of a mutation common 
in a subsection of the Taiwanese population that predisposes such patients to early onset of Parkinson’s disease.  See 
id. 
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These ADRs also have inspired the FDA to conduct pharmacogenomic studies that 
require evaluation of toxicity in separate race-based groups. A recent example is FDA approval 
of alosetron hydrochloride for irritable bowel syndrome—the drug Lotronex by 
GlaxoSmithKline.118 After an initial approval through the FDA, the drug was voluntarily 
withdrawn by GlaxoSmithKline because of ADRs.119 However, because of its efficacy, 
Lotronex was re-approved by the FDA in 2002 with market restrictions.120 Currently, 
GlaxoSmithKline is studying the relationship between adverse events and genetic profiles as part 
of FDA-imposed post-marketing commitments.121 
The FDA also has required race identification in clinical trial design.  In 2003, the FDA 
demanded greater scrutiny of data from subpopulations and required incorporation of racial 
catagories specified by the Census Bureau to ensure consistent evaluation of drug safety profiles 
across racial groups.  Then, in 2005, the FDA issued its first approval of a “race-specific” 
 
117 China has several biobanking initiatives underway that position the nation for leadership in pharmacogenomic 
studies.  See generally, Jiang, C., Thomas, G. N., Lam, T. H., Schooling, C. M., Zhang, W., Lao, X., et al., Cohort 
Profile: The Guangzhou Biobank Cohort Study, a Guangzhou-Hong Kong-Birmingham collaboration, 35 INT. J. 
EPIDEMIOL 844-852 (2006).   The Guangzhou biobank (GBCS), for example, is a collaborative project between the 
UK and China and focuses on older people aged at least 50 years in a mega-city of approximately 10 million.  See 
id.  Of these, 6.4 million are permanent residents with locally registered households, and the remainder are mostly 
migrants from other parts of the country.  See id. Guangzhou, the provincial capital of Guangdong province in 
southern China, is one of the most economically developed regions of China.  See id. The overall study population 
design calls for 30,000 participants who are evaluated regularly by the bank.  See id. The elderly population in 
Guanzhou is uniquely exposed to two unique macroenvironments. Prior to 1949, this was a rural region.  See id.
After formation of the People’s Republic of China, the region was industrialized.  See id. Thus, potential early 
genetic cues may differ substantially between the elderly population that developed through adolescence prior to the 
1949 transition.   See id.  
118 Webster, W., Martin, P., Lewis, G. & Smart, A., Integrating Pharmacogenetics Into Society: In Search of a 
Model, 5 NATURE REV. GENET. 663–669 (2004).   
119 See id 
120 See id. 
 
121 See id. 
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therapy— a fixed-dose combination of isosorbide dinitrate and hydralazine, now known as 
BiDil, NitroMed, for use in African Americans with heart failure. 122 
These events culminated in a 2005 FDA recommendation to pharmaceutical companies 
that they include racial and ethnic data in their safety assessment protocols.  The FDA adopted 
the “Guidance for Industry: Collection of Race and Ethnicity Data in Clinical Trials,” originally 
issued by the Office of Management and Budget (OMB).123 This Guidance advises 
pharmaceutical companies how to incorporate race and ethnicity in a standardized fashion within 
existing protocols for pharmaceutical safety assessment of drugs.124 Under OMB Directive 15, 
race and ethnic classifications are used for administrative practicality, based on the definitions 
provided in the United States Census (Statistical-Directive-15, 1978). 125 The classifications also 
are used by government entities in a range of programs that require consideration of race with the 
objective of achieving inclusion where there has been a legacy of the opposite, including in 
biomedical research.126 Consequently, inclusion of race in pharmacogenomic safety assessment 
profiles for new drug applications is an increasingly accepted practice in the United States. 
 
122 Bibbins-Domingo, K., & Fernandez, A., BiDil for Heart Failure in Black Patients: 
Implications of the U.S. Food and Drug Administration Approval, 146 Ann Intern Med. 52-56 
2007.  See also infra notes 144-150 and accompanying text.  Originally, the FDA rejected the 
drug because its efficacy in treating heart failure could not be demonstrated statistically in a 
clinical trial in the general population   Franciosa, J. A., Fixed Combination Isosorbide Dinitrate-
Hydralazine for Nitric-Oxide-Enhancing Therapy in Heart Failure, 7 EXPERT OPIN 
PHARMACOTHERAPY 2521-2531 (2006).  However, the results of a subsequent doubleblind, 
randomized clinical trial in 1,050 self-identified African-American patients who had experienced 
heart failure were impressive enough to compel the FDA’s race-specific approval.  See id.
123 Finding-Solutions-to-Health-Disparities: Racial and Ethnic Approaches to Community Health (REACH) in the 
U.S. (Oct. 11, 2007), available at http://www.cdc.gov/reach/reach_2010/index.htm.
124 Id.
125 Id.
126 Id.
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. Supporters emphasize the jolt in the scale of genetics research post completion of the map 
of the human genome in 2001 to a level of intricacy dimensions beyond the capabilities of 
genetic science in the years before.127 Today, many scientists are working at the level of 
alterations in single nucleotides (just one adenine, cytosine, quinine, or thymine nucleotide base 
among an individual’s three billion base pairs), and some even are identifying hereditary genetic 
differences through environmental exposures that occur without changes in DNA.128 
These proponents point to the ample positive outcomes of race and ethnicity-based 
research, including findings from research in Amish129 and Ashkenazi Jewish populations,130 and 
the higher incidence of some diseases associated with specific racial and ethnic groups, such as 
Tay Sachs in Ashkenazi Jews131 and cystic fibrosis in Caucasians with Northern European 
ancestry.132 They assert that race and ethnicity should be accepted as a possible research variable 
especially in light of how environmental factors interact with and influence genetics, the 
influence of race and ethnicity on how we group ourselves socially, the impact of these 
 
127 See supra notes 55-58 and accompanying text. 
 
128 This field, epigenetics, is addressed supra notes 21, 22, 53, infra note 117, and in the accompanying text. 
 
129 See, e.g., Robert Wells, Intellectual Property Ownership Issues, 66 LA. L. REV. 69, 74 (2005) (discussing 
collaboration between Affymetrix and Amish populations to identify the gene responsible for Swyer Syndrome and 
a gene responsible for a new form of sudden infant death syndrome). 
 
130 See, e.g., S.V. Hodgson et al., Risk Factors for Detecting Germline BRCA1 and BRCA2 Founder Mutations in 
Ashkenazi Jewish Women with Breast or Ovarian Cancer, 36 J. MED. GENETICS 369 (1999). 
 
131 National Institute of Neurological Disorders and Stroke, available at 
http://www.ninds.nih.gov/disorders/taysachs/taysachs.htm (last visited June 4, 2007).   
 
132 National Heart Lung and Blood Institute, available at 
http://www.nhlbi.nih.gov/health/dci/Diseases/cf/cf_risk.html (last visited June 9, 2007).
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groupings on environmental exposures, and the fact that race and ethnicity have influenced social 
groupings for centuries. 133 As explained by some researchers: 
For example, individuals living in sub-Saharan rural Africa have close to 100% of what 
are called African alleles, whereas African Americans living in the United States show 
about 26% Caucasian admixture 18.  Some groups (for example, African-American, 
Caribbean and Panamanian populations) are likely to show a large degree of allelic 
diversity, whereas other groups (for example, sub-Saharan Africans, Inuits and Finns) are 
less genetically diverse.  Old Amish individuals share more alleles than do individuals in 
other populations because they marry within their own community and as a result have a 
higher than-average incidence of inborn errors of metabolism 19, as do some Arab 
consanguineous communities.  Because of founder effects and enforced segregation, 
Ashkenazi Jews also share a large number of alleles.134 
Much more subtle, the field of epigenetics is demonstrating that environmental exposures and 
lifestyle choices—again, factors highly influenced by social, cultural and geographic 
groupings—impact gene expression in a heritable manner without changes in DNA.135 
Proponents also emphasize the potential good that could be done for the populations of 
developing countries, while also improving the safety and efficacy of biopharmaceuticals across 
subpopulations in developed ones, by recognizing the disparate impact pharmaceuticals have on 
subpopulations organized by race, ancestry, and ethnicity in advance of their market 
distribution.136 They emphasize that, today, the measures for market access in the United States 
are crude—the standard is better than placebo, biopharmaceuticals are often put on the market 
with a showing of efficacy in only thirty-percent of the subjects, and usually only after being 
 
133 See generally Race, Ethnicity, and Genetics Working Group, The Use of Racial, Ethnic, and Ancestral 
Categories in Human Genetics Research, 77 AM. J. HUM. GEN. 519-32 (2005); See generally Cohn, Lessons, supra 
note 9; Bhopal, Responsible Use, supra note 9; Burchard, Importance of Race, supra note 9.  
 
134 Daar & Singer, Pharmacogenetics, supra note 105, at 242. 
 
135 See supra notes 22 & 53 and accompanying text.  [Damon, please research tangible successes in epigenetics 
research to date]. 
136 See, e.g., id. 
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tested on the general populations of Europe and North America.137 And, in fact, countries 
largely excluded from biopharmaceutical R&D are responding by establishing their own 
ancestry-based genotyping initiatives—countries including China, India, Indonesia, Japan Korea, 
Malaysia, Mexico, Nepal, the Philippines, Singapore, Taiwan, and Thailand138—and even 
transnational efforts, such as The Pan-Asian Initiative.139 
C. The Debate Applied: HapMap and BiDil 
One of the most controversial research undertakings in recent years is the International 
Haplotype Mapping Project (“HMP”),140 a collaboration among scientists and funding agencies 
from Canada, China, Nigeria, the United Kingdom, and the United States.141 The goal of HMP 
 
137 Id. at 243.  The number of adverse events and performance disappointments with biopharmaceuticals in recent 
years speaks to this.  See generally Congressional Committee Report (Dec. 2007); Institutes of Medicine Report 
2006; General Accountabililty Office Report (2006). 
 
138 Populations outside of North America and Europe are recognizing the problems of exclusion and potential 
benefits of inclusion in biopharmaceutical R&D, and they are undertaking initiatives, sometimes in collaboration: 
India and Thailand are both embarking on SNP-genotyping studies.  Hosted by the Genome Institute of 
Singapore, an important regional initiative has recently brought scientists from China, India, Indonesia, 
Japan, Korea, Malaysia, Nepal, the Philippines, Singapore, Thailand and Taiwan to establish the Human 
Genome Organization (HUGO) Pacific Pan-Asian SNP Initiative, which is expected to begin in the middle 
of 2005.  The goal of this initiative is to uncover the breadth of genetic diversity and the extent of genetic 
similarity within Asian populations.  This information will form the basis for future studies in genomic 
medicine focused on Asian populations.  Data from the Pan-Asian study will provide a platform for 
researchers in Asia to study why some populations seem predisposed to certain diseases, or do not respond 
to certain drugs. Cost reductions and new technologies are opening up the study to all researchers, 
including those with less well-developed research infrastructures.  Asia is not alone in such initiatives.  
Mexico has a newly-created, well-funded federally mandated Institute of Genomic Medicine, headed by 
Gerardo Jimenez-Sanches.  Genotyping the diverse Mexican populations is one of its top priorities.  
 
Daar & Singer, Pharmacogenetics, supra note 105, at 242. 
 
139 See supra notes 112-117 and accompanying text. 
 
140 For more information, visit the official site of the International Haplotype Mapping Project, at 
http://www.hapmap.org/ (last visited June 2, 2007) and the National Human Genome Research Institute (NHGRI) 
HapMap Page, http://www.genome.gov/page.cfm?pageID=10001688 (last visited July 12, 2007). See generally 
Clayton, Implications, supra note 34; Ossorio, Haplotype Mapping Project, supra note 34. 
 
141 Visit Haplotype site, supra note 34; NHGRI HapMap Page, supra note 35.  See generally Daar & Singer, 
Pharmacogenetics, supra note 105, at 242. 
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is to take the concept of familial-pedigree studies up to the population level—to compare genetic 
sequences to identify chromosomal regions where genetic variants are shared, and to identify 
clusters of variations that are inherited together.142 Stage I of HMP, commenced in October 
2002 and completed in fall 2006, consisted of analyzing DNA from populations with African, 
Asian, and European ancestry.143 This chapter of HMP resulted in a haplotype map consisting of 
more than 1 million SNPs.144 The Consortium’s goal for Phase II, financed with $3.3 million in 
public-private support, is to create a map five-times denser.145 Data is made available to the 
global science communities on an ongoing basis through free public databases.146 HMP already 
has enabled considerable population-based genetics research through its contributions to cost-
effectiveness.147 
In addition to the science that HMP has generated, the project has made a tremendous 
bioethics contribution to the field of population genetics and genetics research in general.  HMP 
has introduced a prototype ethics model for population genetics research with ancestry, race and 
 
142 Visit Haplotype site, supra note 34; NHGRI HapMap Page, supra note 35. 
 
143 Samples were collected from 270 people in these three groups: Africans (30 sets of familial samples from the 
Yoruba people of Ibadan, Nigeria); Japanese (45 unrelated individuals from the Tokyo area); Chinese (45 unrelated 
individuals from Beijing); and Europeans (30 trio samples from European-Mormon families in the U.S.). Visit 
Haplotype Mapping, supra note 52. 
 
144 NIH News Release, International HapMap Consortium Expands Mapping Effort (Feb. 7, 2005), available at 
http://www.genome.gov/13014173 (last visited May 27, 2007).
145 See id. This support includes the Wellcome Trust, London, $624,000; Genome Canada/Genome Quebec, 
$260,000; Bristol-Myers Squibb Co., New York, $100,000; Pfizer Inc., New York, $100,000; Perlegen Sciences, at 
least $1.2 million (based on "in kind" services); and NHGRI, $1 million.  Id.  
146 These databases include the HapMap Data Coordination Center, www.hapmap.org (last visited  June 12, 2007), 
the NIH-funded National Center for Biotechnology Information's dbSNP,
http://www.ncbi.nlm.nih.gov/projects/SNP (last visited June 6, 2007), and the JSNP Database in Japan, 
http://snp.ims.u-tokyo.ac.jp/ (last visited July 23, 2007).  
147 See generally Daar & Singer, Pharmacogenetics, supra note 105, at 243-244. 
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ethnicity implications. 148 The Ethics Committee for HMP, co-chaired by Professors Ellen 
Wright Clayton and Bartha Knoppers, has generated guidance and algorithms used in the project, 
which include obtaining group consent when practicable and appropriate.149 
Another significant controversy in race-based genetics that has raised the volume of the 
debate was the Food and Drug Administration’s approval of BiDil for treatment of heart failure 
specifically in African Americans (“blacks” is used on the label insert).150 The decision, issued 
on June 23, 2005, was the first FDA approval of a pharmaceutical use limited to a specific racial 
or ethnic group.151 The drug did not originate from a race-based population genetics 
methodology,152 but it was approved based upon one—a study of 1,050 self-identified black 
patients with severe heart failure who had already been treated with the best available therapy.153 
According to the FDA, this study demonstrated that black patients on BiDil experienced a forty-
 
148 See generally, Implications, supra note 35.  The HMP also has a staff committed to related ethical, legal, and 
social implications issues, which includes Vivian Ota Wang, Jean McEwen and Lisa Brooks.  The staff may be 
contacted at: 
National Human Genome Research Institute 
National Institutes of Health 
5635 Fishers Lane 
Suite 4076, MSC 9305 
Bethesda, MD 20892-9305  
Phone: (301) 496-7531 
Fax: (301) 480-2770   
 
149 See generally Clayton, Implications, supra note 35.  See supra note 17. 
 
150 See supra note 112 and accompanying text.  According to the BiDil package insert, “BiDil is indicated for the 
treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to 
prolong time to hospitalization for heart failure, and to improve patient-reported functional status.”  BiDil Package 
Insert at p. 9 (on file with author).   
 
151 See Kahn, Racial Categories, supra note 9, at 15-16; Hoffman, Unraveled, supra note 9, at 396; Rene Browser, 
Race As A Proxy for Drug Response: The Dangers and Challenges of Ethnic Drugs, 53 DEPAUL L. REV. 1111, 1112 
(2004); Gregory M. Lamb, A Place for Race in Medicine?, THE CHRISTIAN SCI. MONITOR, Mar. 3, 2005, at 14.   
 
152 Two general population studies indicated no clinical benefit, but sponsors spotted a potential benefit in a 
subpopulation of subjects who self-identified as black.  FDA News, FDA Approves BiDil Heart Failure Drug For 
Black Patients (June 23, 2005), available at http://www.fda.gov/bbs/topics/NEWS/2005/NEW01190.html (last 
visited July 12, 2007). 
 
153 Id. 
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three percent reduction in death, a thirty-nine percent decrease in hospitalization for heart failure 
compared to a placebo, and a decrease of heart failure symptoms.154 Although the BiDil 
sponsor’s methodology, data, and patent practice were challenged and criticized intensely in the 
law literature,155 the FDA’s decision stands and the underlying data has survived scientific and 
clinical scrutiny from the medical and science communities.156 
Nevertheless, challenges from the law and social science communities linger.  One 
concern is that, because members often identify with racial and ethnic groups strongly, they will 
demand drugs associated with their racial and ethnic group affiliations regardless of other good 
medicine considerations and options, and physicians will give into those demands.157 Such a 
scenario could exacerbate standing differences in health care quality due to race-based medicine, 
as documented by the Agency for Health Care Research and Quality (AHCQ).158 Another is that 
 
154 Id. 
155 Professor Jonathan Kahn has challenged the integrity of re-analysis of the general population trial data and the 
sponsor’s associated patent claim based upon the race-specific science findings, which extended patent protection of 
BiDil from 2007 to 2020 and made the large African-Americans trial and commercialization post-approval 
commercially viable.  Kahn, supra note 9, at 15-16.  See also Bhopal, Responsible Use, supra note 9.  Professor 
Roberts has repeated Professor Kahn’s concern and declared “race-based pharmaceuticals promise to be a lucrative 
field of invention.”  Roberts, Legal Constraints, supra note 9, at 528-529.  However, it would not make economic 
sense for sponsors of pharmaceuticals to choose to limit their use to a particular race if they can demonstrate safety 
and efficacy in the general population.  The scientific outcome of the African American clinical trial of Bidil 
supports the integrity of the underlying patent claim, and the patent system appears to have worked:  a drug with 
clinical utility in African Americans which would not have been developed now is available to them and their 
doctors as a treatment option for a life-threatening condition.  See generally Cohn, Lessons, supra note 9. 
 
156 See generally Cohn, Lessons, supra note 9; Bhopal, Responsible Use, supra note 9. 
 
157 Hoffman, Unraveled, supra note 9, at 419-426. 
 
158 Id. AHRQ has documented significant treatment disparities for major diagnostic related groups (“DRGs”) where 
there was a baseline of coverage and access to care.  In comparison with Caucasian patients in the same DRGs, 
doctors provided significantly fewer and less aggressive treatments for patients with ethnic and racial affiliations.  
See AHRQ, National Health Care Disparities Report 2006 (2006), available at 
http://www.ahrq.gov/qual/nhdr06/nhdr06.htm (last visited July 17, 2007).  In fact, tremendous disparity in health 
care treatment for common and serious conditions has been documented in the U.S., causing some to suggest that, 
rather than an art or science, medicine in the U.S. is guesswork.  John Carey, Medical Guesswork: From Heart 
Surgery to Prostate Care, the Health Industry Knows Little About Which Common Treatments Really Work, 3986 
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the biopharmaceutical sector will accomplish the same commercial responsiveness through 
aggressive marketing, thereby exploiting racial and ethnic groups and detracting from their 
health care.159 Professors Lillquist and Sullivan suggest that the medical community will not 
move beyond race-specific data—meaning they will not engage in significant off-label use in 
patients with the disease but without the race affiliation—to the potential medical disadvantage 
of other populations.160 Others worry about the success of BiDil encouraging more race-based 
research and exploitation of groups associated with the clinical study on African Americans.161    
 Dr. Jay Cohn, Director of the Rasmussen Center for Cardiovascular Disease Prevention at 
the University of Minnesota and a renowned clinical researcher, has responded to these 
challenges to BiDil with arguments based in science and a focus on good medicine.162 Dr. Cohn 
was the lead investigator and inventor on a patent for BiDil (combining isosorbide dinitrate and 
 
BUS. WK. 72-84 (May 29, 2006).  Presumably, over time, increased precision from genomics will spill into medicine 
and lessen these disparities. 
159 Question and answer session of Race-Based Research Session, Health Law Teachers Annual Meeting (June 
2006) (attended by the author).  It is important to note, however, that the sponsor of BiDil first attempted to establish 
the safety and efficacy of its drug in the general population, which proved unsuccessful.  FDA approval for use in 
the general population accompanied with the release of data suggesting greater efficacy in African Americans would 
have proven a more profitable market strategy, but one not supported by the clinical data.  See supra notes 111-112 
and accompanying text.  It is unlikely that biopharmaceutical companies will intentionally limit the scope of their 
market approvals, for they have been hesitant even to introduce pharmacogenomic data out of fear that the use of 
their products will be conditioned on genetic screening and the presence of particular genetic alleles.  See generally 
Janet Woodcock, FDA Policy on Pharmacogenomic Data in Drug Development, 66 LA. L. REV. 91 (2005). 
 
160 See also Lillquist & Sullivan, supra note 9, at 542.  However, the medical profession does engage in extensive 
off-label use, and the sponsors of pharmaceuticals limited to a specific racial group would have every economic 
incentive to undertake post-marketing clinical research to broaden their market access—i.e., find safety and efficacy 
in additional populations. 
 
161 Prof. Troy Duster, Dinner Presentation, "The Globalization of Pharmaceutical Development: Race, Markets and 
Ethics" (Mar. 16, 2006, Santa Clara College of Law) (addressing the "shift from genetic sameness to individuality" 
pre- and post-HGP); Troy Duster, Lessons from History: Why Race and Ethnicity Have Played a Major Role in 
Biomedical Research, 34 J.L. MED. & ETHICS 487 (2006); Troy Duster, Race and Reification in Science, 307 SCI.
1050, 1050 (2005). 
162 Cohn, Lessons, supra note 9, at 1.   
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hydralazine).163 As stated by Dr. Cohn, from the perspective of a medical doctor and clinical 
investigator, 
The debate . . . should not be over the existence of population differences, but 
how to describe those differences with more precision. Those who argue against 
our current approach may wish that differences did not exist, but they do. They 
are identified by statistical differences among definable populations in prevalence 
and physiological mechanisms. These population differences cannot in the first 
instance be classified as genetic, geographic, or environmental. They are observed 
differences in populations identified by a variety of demographic criteria. Railing 
against what some claim are misguided efforts to use racial, ethnic, or geographic 
distinctions does not make the differences disappear. We should be working 
toward better approaches in dealing with the differences, not raising legal and 
moral arguments, as Professor Roberts has, claiming that any effort at distinction 
is wrong.164 
IV. An Illustrative Case Study in Population Genetics 
Responsible biobanking in any group introduces the potential to benefit the group under 
study regardless of how that group is organized.  These benefits include opportunities to increase 
the level of communication between the group and the research community to raise sensitivity to 
the group’s particular social and cultural norms, to participate at the forefront of genetics 
research, to control the terms of that participation, and to realize commercial benefits and 
scientific and medical returns.  More generally, the endeavor advances bioethics through 
population genetics case study applications and, scientifically and medically, introduces the 
possibility of benefiting humankind well beyond the group under study due to the youth and 
genetic sameness of our species.  
 
163 Wolf, Debating Use, supra note 52, 483. 
 
164 Cohn, Lessons, supra note 9, at 556.  Professor Roberts proposes applying law to “discourage or prohibit the use 
of `race’ as a genetic or biological category, but encourage or require the use of `race’ as a sociopolitical category to 
understand and investigate ways to eliminate disparities in health status, access to health care, and medical 
treatment.”  Roberts, Legal Constraints, supra note 9, at 532-533.    
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To illustrate these points, the scientific complexities and unpredictability of population 
genetics, and the potential benefits of any serious, responsible population genetics undertaking, 
consider the incidents of dwarfism embodied by Matt Roloff, his wife Amy, and their son Zach.  
The Roloff case study places population genetics in a tangible context that utilizes a genetic 
disease-based organizing criteria much more acceptable to opponents of race and ethnicity based 
genetics research.  The case study also is responsive to some of the fundamental challenges to 
race and ethnicity-based genetics research raised by these opponents.  First, it demonstrates the 
extent to which groups organized by genetic disease may be no more homogenous than groups 
organized by race and ethnicity, and even less so.  Second, this case study underscores that, 
regardless of the collection criteria, responsible biobanking may be advantageous on multiple 
levels, including group communication, empowerment, and benefits.    
Matt, Amy, Zach are dwarfs who are featured in the television show “Little People, Big 
World” along with Zach’s siblings—Jeremy, Molly, and Jacob—who do not have dwarfism.165 
To the casual observer, the Roloffs represent an extreme in genetic homogeneity given their 
biological ties to each other and the incidence of dwarfism in their immediate family.  Many 
would be comfortable extending this perceived genetic grouping to encompass other people with 
 
165 For information about the show and the Roloff family, visit the Roloff Family internet site at 
http://www.mattroloff.com/ (last visited June 9, 2007). Slide Show, Dwarfism,
http://www.mansfield.osu.edu/~jbradley/102Ppts/Dwarfism.ppt. (last visited Feb. 7, 2007).  Information about DD 
is available at Little People of America Online, FQs, http://lpaonline.org/resources_faq.html (last visited May 28, 
2007); Luise Bonafe & Andrea Superti-Furga, Diastrophic Dysplasia, (posted Nov. 15, 2004), available at Gene 
Review,  http://www.genetests.org/query?dz=diastrophic-d (last visited May 24, 2007). See also PBS, What is 
Dwarfism, available at http://www.pbs.org/pov/pov2005/bigenough/special_dwarfism.html (last visited Apr. 16, 
2007)..  See generally PBS, “Big Enough”, aired Aug. 8, 2006; Clinical Implications of Basic Research: The 
Genetic Basis of Dwarfism, NEW ENG. J. MED., vol. 332, no. 1, 58-59 (Jan. 5, 1995).  Information about 
achondroplasia dwarfism is available at Clair A. Francomano, Achondroplasia, available at GeneReviews, 
http://www.geneclinics.org/profiles/achondroplasia/details.html (updated Jan. 9, 2006) (last visited Feb. 7, 2007);
March of Dimes, Quick Reference and Fact Sheets: Achondroplasia, available at 
http://www.marchofdimes.com/professionals/681_1204.asp (last visited Feb. 7, 2007).  The popularity of Little 
People, Big World has inspired “The Foos Family,” the real TV profile of a family with dwarfism throughout.  For 
information about the Foos, visit http://www.advancedmedical.tv/shows/mtf.htm#synapsis (last visited Apr. 14, 
2007).   
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dwarfism given that it is commonly recognized as a genetic condition.  However, there are more 
than two hundred forms of dwarfism, which appears throughout recorded history and affects both 
sexes and all races.166 Matt has diastrophic dysplasia (“DD”), the third most prevalent type of 
dwarfism, which occurs once in every 110,000 births in the U.S.167 Although DD arises in all 
races and sexes, there is a higher incidence rate in Finland.168 Symptoms associated with DD 
include a cleft pallet, a “hitchhiker thumb” (a thumb permanently distended), club feet, and other 
orthopedic and joint problems that impact shoulders, elbows, hips and knees.169 The gene for 
DD, SLC26A2, is on chromosome 5q32-q33.1 and it is recessive. 170 A parent may carry the 
gene but not have DD, and both parents must carry the gene—not necessarily have DD—to have 
a child with DD.171 Typically, children with DD are born to two parents who each carry the DD 
gene but do not have DD. 172 Under these circumstances, there is a fifty percent chance that each 
child will be a carrier of DD but not have dwarfism, a twenty-five percent chance that the child 
 
166 Official The Learning Channel (TLC) homepage for “Little People, Big World”, available at 
http://tlc.discovery.com/fansites/lpbw/lpbw.html. (last visited Mar. 19, 2007). 
 
167 Little People of America Online, FQs, http://lpaonline.org/resources_faq.html (last visited June 2, 2007).
Information about DD is available at Diastrophic Dysplasia, Genetics Home Reference, at 
http://ghr.nlm.nih.gov/condition=diastrophicdysplasia;jsessionid=A16D3AB4538E86E2F34B6065DCEDA343 (last 
visited Feb. 7, 2007); Greenberg Center for Skeletal Dysplasis, available at 
http://www.hopkinsmedicine.org/greenbergcenter/tutorial.htm (updated Sept. 12, 2002) (last visited Feb. 7, 2007). 
The most common form of dwarfism, achondroplasia, occurs in one per 26,000-40,000 births. Id. The entire world-
wide dwarf population was estimated to be 6,250,000,000 in 2002.  Dwarfism.Org, at http://www.dwarfism.org/ 
(last visited June 7, 2007).
168 Greenberg Center for Skeletal Dysplasis, available at 
http://www.hopkinsmedicine.org/greenbergcenter/tutorial.htm. (updated Sept. 12, 2002) (last visited Feb. 7, 2007). 
169 Id. 
170 See generally id.  
171 http://www.pixelscapes.com/ddhelp/DD-booklet/ (last visited Apr. 14, 2007). 
 
172 See generally Bonafe & Andrea, supra note 124. 
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will have DD (have a pair of SLC26A2 genes, one from each parent), and a twenty-five percent 
chance that the child will be unaffected.173 
Matt’s wife Amy and son Zach have achondroplasia (“AP”), the most prevalent form of 
dwarfism, which occurs in one out of every 25,000 births and, like DD, affects both sexes and all 
races.174 However, the gene for AP, FGFR3, is dominant, so it is symptomatic in everyone who 
carries FGFR3.175 Eighty percent of AP children are born to parents of normal stature, meaning 
that AP usually is the result of a de novo gene variation.176 When both parents have AP, each 
carries the FGFR3 gene and its non-AP counterpart, meaning that they have a fifty percent 
chance of having a child with AP (one FGFR3 gene paired with a non-AP counterpart), a twenty-
five percent chance of having a child without AP (two non-AP genes), and a twenty-five percent 
chance of having a child with two FGFR3 genes.177 This latter condition, known as homozygous 
AP or double homozygosity, usually is fatal.178 
The Roloffs had no chance of having a child with DD because Amy is not a carrier of 
SLC26A2.179 Matt does not have AP and does not carry FGFR3.  Therefore, with each 
pregnancy, Amy and Matt had a fifty percent chance of parenting a child with AP, and all the 
Roloff children—including Jeremy, Molly, and Jacob who are of normal stature—are carriers of 
 
173 See generally id.
174 See generally A Francomano, GeneReview, supra note 124. 
 
175 See id 
.
176 See id.  
177 See id. 
178 See id.  There are exceptions, however, such as one of the children in the Foos family.  See supra note 123. 
 
179 Roloff Family, Internet site, supra note 124. 
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DD.180 Among Matt, Amy, and Zach, all are dwarfs according to phenotype and, therefore, they 
share many challenges posed by their environment on a daily basis—for example, extreme stress 
on their hips and knees due to the size of their heads and torsos in relation to their limbs.  Their 
symptoms overlap significantly, though some are distinguishable—for example, the severity of 
Matt’s joint and orthopedic problems associated with DD, which cause him to rely upon walkers 
and occasionally electronic ambulatory machinery for movement.181 However, genetically, their 
DD and AP differences make them highly distinguishable.   Combining these fundamental 
genotype and phenotype characteristics, there is a lot of genetic complication within the Roloff 
family: according to phenotype, three incidents of dwarfism among a family of six, with both 
overlapping and distinguishable symptoms; two forms of dwarfism with completely different 
genetic causes, one a dominant gene and the other a recessive gene, on different chromosomes; 
and four children who are carriers of DD, including three who are of normal stature.182 
Although the societal perceptions used to group the Roloffs and people with dwarfism in 
general are at best an exaggeration of genetic reality, the Roloffs could advance the realization of 
bioethics principles in population genetics and make significant contributions to genetics 
research in and beyond dwarfism.  Imagine that the Roloffs decide to use their celebrity to 
advance research on dwarfism by establishing littlepeopleBiobank (“lpBiobank”), a biobank of 
families in the U.S. with at least one occurrence of a child with dwarfism.183 Little people with 
 
180 With each pair of genes, offspring get one version of the relevant gene from each biological parent.  Matt only 
has DD genes to pass onto each child.   
 
181 TLC Homepage, supra note 124.   
 
182 See supra notes 125-131 and accompanying text. 
 
183 Biobanks are the collection and organization of biological samples, medical information, and sometimes 
environmental data for research use.  For a comprehensive treatment of biobanking, see generally Symposium: 
Regulation of Biobanks, 33 J. L. Med. & Ethics 1-188 (Mark Rothstein & Bartha Knoppers eds., 2005).  A number 
of governments have undertaking biobanking initiatives, including Estonia, Iceland, Japan, Singapore, Sweden, and 
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dwarfism in the United States are highly organized on the national, regional, and local levels 
through the not-for-profit organization Little People of American (“LPA”), and they share strong 
social group identification.184 Throughout its half-century of existence, LPA has united the 
community through its many social activities, including conferences and other events, and by 
serving as an information resource. 185 LPA has earned the trust of its members, as evidenced 
through their active and ongoing participation.186 The organization of the group and its 
governance structure suggests a means to work through bioethics issues such as individual 
consent, group impact, and group consent with sensitivity and insight.187 LPA also could 
provide a means to identify acceptable conditions for research protocols and workable terms for 
technology transfer around the lpBiobank, such as the requisite quid pro quo for researcher 
access.188 Presumably the scope of the lpBiobank, both in terms of samples and accompanying 
medical information, and the sophistication of its organization and ability to meet individual 
researcher needs would be somewhat proportional to the group’s bargaining power with 
researchers and research institutions.189 
the United Kingdom   Representatives from these biobanks were gathered in August 2007 for the Meeting to Launch  
the Taiwan Biobank, in which the author participated.  Proceedings, Meeting to Launch the Taiwan Biobank, 
Academia Sinica,  Taipei, Taiwan, Aug. 12-15, 2007. 
 
184 For more information, visit LPA Online at http://www.lpaonline.org/lpa_intro.html (last visited Feb. 9, 2007).  
LPA membership to which is offered to individuals 4’ 10’’ and shorter.  See id. 
185 See supra note 143. 
 
186 LPA has over fifty local chapters which meet monthly and hosts a range of activities, including an annual week-
long national conference that typically draws 1,000 or more attendees.  Visit LPA Online at 
http://www.lpaonline.org/lpa_intro.html (last visited Feb. 9, 2007).   
 
187 See generally Henry Greely, Population Participation and Other Factors that Impact the Compilation and the 
Utility of Resulting Databases, 66 LA L. REV. 79 (2005).  See also Bartha Maria Knoppers, Biobanking: 
International Norms, 33 J. L. MED. & ETHICS 7, 10 (2005).   
 
188 Malinowski, Technology Transfer, supra note 37, at 59.  
 
189 For an excellent case study in biobanking, see the discussion of Pseudoxanthoma Elasticum (PXE) in David E. 
Winickoff, Governing Population Genomics: Law, Bioethics, and Biopolitics in Three Case Studies, 43 
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If lpBiobank were formed, the basic phenotype characteristics associated with dwarfism 
would unite people who embody a range of distinct genes that cause their distinguishable version 
of the condition—meaning a phenotypically homogenous group, idiosyncratically so to the 
layperson, that actually embodies a lot of genetic diversity.190 It is theoretically possible that 
there could be less overall genetic commonality among the lpBiobank members than among 
another group that, based on phenotype, appears more genetically diverse to society.  For 
example, there may be more genetic commonality among the one hundred and seventy-five 1Ls 
at Yale Law School, a heavily screened group selected, among other things, to achieve diversity 
as defined by society (or at least law school administrators).191 Greater genetic commonality 
might also be  found between the subpopulation of the lpBiobank with DD and the Yale 1Ls, for 
SLC26A2 is but one of the 3,000,000 distinct DNA variants estimated to separate any two 
unrelated human beings.192 Similarly, the females in lpBiobank may share more overall genetic 
commonality with the first year class at Wellesley College, an all-women school, than with their 
male lpBiobank co-members.  Also, given the higher incidence of DD in Finland, the DD 
members of the group may share more overall genetic commonality with the population of one 
 
JURIMETRICS J. 187,  222-226  (2003).  See generally Malinowski, Technology Transfer, supra note 37 (discussing 
PXE and other case studies).  Another excellent case study of how groups may use biobanking to advance research 
they desire is that of The Pan Asian Initiative, which is addressed infra in notes 112-117, 213 and accompanying 
text.    
 
190 See generally LPA Online at http://www.lpaonline.org/lpa_intro.html (last visited Feb. 9, 2007); PBS, What is 
Dwarfism, available at http://www.pbs.org/pov/pov2005/bigenough/special_dwarfism.html (last visited Aug. 6, 
2007).   
 
191 This conclusion is suggested by the body of work generated by Luca Cavalli-Sforza.  See supra notes 22-23 and 
accompanying text.  
 
192 See supra note 42 and accompanying text. 
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or more of the small, scattered, isolated settlements in Northern and Eastern Finland than with 
their lpBiobank counterparts.193 
Nevertheless, lpBiobank may prove a valuable resource to develop bioethics algorithms 
for researchers working on DD and AP and population genetics in general.  Moreover, even if 
the lpBiobank membership were limited to people with DD and AP dwarfism, researchers 
working on other forms of dwarfism also may take interest because some of the more 
fundamental phenotype characteristics (shared cellular differentiation) of dwarfism transcend the 
groupings.  Comparing and contrasting the expression of a particular phenotype characteristic 
among subpopulations in the lpBiobank could prove a means for identifying and understanding 
the intricate pathways of gene and cellular expression that connect the common phenotype 
characteristic to the highly distinguishable genetic triggers for dwarfism.  In fact, because 
members of the human species are 99.9 percent the same genetically, the lpBiobank could prove 
useful for a wide array of genetics research not necessarily associated with dwarfism depending 
on how extensive the biobank is and the type and quantity of medical information available to 
researchers.  It follows that research findings by those working within the lpBiobank may readily 
transcend the DD population—for example, fundamental understanding about genetic expression 
and cellular differentiation in the general human population.  Moreover, in addition to any direct 
benefits to members of lpBiobank, the endeavor could contribute immensely to population 
genetics in general through development of thoughtful recruitment, consent algorithms, and 
technology transfer precedents.  Working within a group defined by society that self-identifies 
would provide a means to insightful deliberation of group impact.  LpBiobank also might 
193 Today, almost twenty percent of Finland’s population lives in such settlements.  See Andra Aldea-Partoren, Esko 
Lehto, & Jukka Oksa, Access to Services in Rural Finland: Examples from Esko Lehto and Jukka Oksa (Oct. 2004), 
available at http://cc.joensuu.fi/~alma/deserve/raportit/rep04-finland.doc (last visited June 18, 2007).   
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contribute to genetics research and society in general by inspiring similar biobank efforts among 
other groups, thereby creating resources needed to accelerate the process of making medical 
sense out of the human genome map. 
V. A Proposal in Favor of Race-Based Genetics Research 
 The reckless words of Dr. Watson published by the London Sunday Times on October 14, 
2007194 speak to the dangers of using social science to make conclusions about human genetics 
that are not substantiated by existing genetic science.195 This is a lesson learned over the last 
century at tremendous cost to human life, extraordinary human suffering, and incalculable lost 
research opportunities when Charles Davenport, a Cold Spring Harbor predecessor of Dr. 
Watson, established the Station for Experimental Evolution at Cold Spring Harbor and the 
Eugenics Record Office next door.196 Dr. Davenport used Cold Spring Harbor and the Eugenics 
 
194 See supra note 1 and accompanying text. According to the New York Times,  
In announcing his retirement, in an oddly oblique e-mailed dispatch, he expressed hope that the latest 
biological research, at Cold Spring Harbor and elsewhere, would lead to treatments for mental illness and 
cancer.  Invoking his `Scots-Irish Appalachian heritage’ and a faith in reason and social justice passed on 
by his parents, he sounded sad and confused, as though this time he had succeeded in dumbfounding even 
himself. 
George Johnson, Bright Scientists, Dim Notions, NEW Y. TIMES, Oct. 28, 2007, at 5. 
 
195 Although this author’s professional discipline is legal academia and he approaches this material from a base in 
the social sciences, holds deep respect for quality social science research, and appreciates that such research may 
help to frame meaningful natural science research protocols, he is adamantly opposed to overreaching from the 
social sciences to suggest natural science genetic truths.  Last century’s experience with eugenics makes this author 
extremely uncomfortable with some social science-based behavioral biology, which gained significant popularity in 
legal academia in conjunction with the advancement of natural genetics science through HGP.  See, e.g., Owen D. 
Jones & Timothy H. Goldsmith, Behavioral Biology, 105 COLUMBIA L. REV. 405 (2005).  Related emerging fields 
that invite speculation about natural science genetics far removed from established genetics science research include 
“Law and Emotions” and some social science approaches to neurogenetics, a genetics science priority set by Dr. 
Watson for Cold Spring Harbor prior to his resignation.  This is, in the spirit of The Bell Curve (see supra notes 38-
41 and accompanying text), potentially reaching too far beyond established natural science, inviting the substitution 
of extensive speculation for established genetics science, and perhaps influencing law and policy based upon that 
speculation in areas fundamental to the human condition and society.  See Grubbe, Elementary DNA, supra note 1.  
“Law and Emotions” is the subject matter of a major conference hosted jointly by Vanderbilt University and the 
School of Law (Boalt Hall), which will take place Feb. 8-9, 2007.  For more information, visit Law and Emotions, at 
http://law.vanderbilt.edu/academics/scholarly-events/past-events/law-and-the-emotions/index.aspx (last visited Oct. 
26, 2007).    
 
196 See Malinowski, Choosing, supra note 18, at notes 25-181 and accompanying text.  The Station was seeded in 
1904 by a $10 million grant from the Carnegie Institute of Washington, a grant that surpassed the total endowment 
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Record Office to collect shoddy data that substantiated centuries of social observation about the 
human condition, however tainted by prejudices.197 His work gave credibility to a eugenics 
movement that started with a sputter of “fitter families contests” in America’s heartland but then 
roared into an international movement that included involuntary sterilization legislation and 
forced sterilizations in the United States and beyond, provided some precedent for the murder of 
millions the Third Reich deemed “undesireables”, and served as a pretext for the torture of tens 
of thousands, including many children, under the guise of medical research.198 
The immediate outrage of today’s genetics and broader natural science communities in 
response to Dr. Watson’s comments and the global resonation of that protest attest to the extent 
to which the field of human genetics has evolved over the last century, even if some of Dr. 
Watson’s thinking has not.199 The lines between natural science in genetics and the social 
sciences must be respected.  Crossing them is essential, but that must be done with 
thoughtfulness and professionalism—for example, the Ethical, Legal, and Social Implications 
Program counterpart to HGP.200 Just as social science findings should not be substituted for 
established genetic science truths, the legitimacy of responsible genetic science research should 
not be undermined scientifically where the driving force is actually to preempt avoidable social 
harms.  There simply is too much potential benefit to human health at stake to make the lines that 
 
for research in United States universities, while the Records Office was financed through generous support from Ms. 
Mary Harriman, a philanthropic socialite.  Id. at notes 33-35. 
 
197 Id. at notes  37-38 and accompanying text. 
 
198 Id. at notes 68-101 and accompanying text. 
 
199 See, e.g., supra notes 2-3 and accompanying text. 
 
200 Dr. Watson himself and the other founders of the HGP recognized the necessity of accompanying genetics 
research with the social science disciplines to probe ethical, legal, and social implications of the underlying research 
the same, and ELSI has proven an essential counterpart.  Today, there are ELSI counterparts to virtually all major 
genetics research undertakings, including HMP.  For information about ELSI, visit the site of the Human Genome 
Research Institute at http://www.genome.gov/ (last visited Oct. 26, 2007).    
48
faint and fluid.  Identifiable and ominous potential social harms necessitate caution, but the 
answer is to move research forward thoughtfully and responsibly with the strong presence of 
responsive law and policy. 
As articulated thoughtfully by Dr. Raj Bhopal,201 “Race and ethnicity are closely related, 
contentious concepts that have been abused and misinterpreted through history, but have a vast 
potential for good, at least in the health sciences.”202 Similarly, as observed by Dr. Margaret 
Winker, Deputy Editor of the Journal of the American Medical Association, “Despite the many 
difficulties posed by categorizing race, in some instances it can be important to assess race and 
ethnicity.”203 
Race and ethnicity are as real socially and culturally as genetics is scientifically204 and 
“[i]t is well known that disease does not affect the population equally[.]”205 The reality of these 
constructs is made evident by the reactions they compel, their impact on human history, and their 
influences on culture, society, and how individuals perceive themselves and others.206 Race and 
ethnicity influence where people live, how they live, what they consume, and whom they partner 
 
201 Dr. Bhopal, M.D., M.P.H., FRICP (E), CBE, became Professor and Head of the Department of Epidemiology 
and Public Health at Newcastle University in 1991, Alexander Bruce and John Usher Professor of Public Health at 
the University of Edinburgh in 1999, and Head of the Division of Community Health Sciences 2000-03. He is 
Chairman of the Steering Committee of the National Resource Centre for Ethnic Minority Health, Scotland, and 
honorary consultant in public health to the Lothian Health Board. 
 
202 Bhopal, Responsible Use, supra note 9, at 500.   
 
203 Winker, Race and Ethnicity in Medical Research: Requirements Meet Reality, 34 J. L. MED. & ETHICS 520, 521 
(2006). 
 
204 See supra note 14 and accompanying text.  See Ossorrio, About Face, supra note 2, at 278.  See generally 
Working Group, Use, supra note 13. 
 
205 Neil Risch, Dissecting Racial and Ethnic Differences, 354 NEW ENG. J. MED. 408 (2006).  See also notes 92-99 
and accompanying text.  See generally Cohn, Lessons, supra note 6; Bhopal, Responsible Use, supra note 6.  
 
206 See id. 
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and propagate with—often significantly.207 Moreover, they have done so for many generations; 
historically, race and ethnicity have profoundly impacted what environmental exposures people 
have been subjected to, and their influence continues.  “Put simply, place has a huge impact on 
health for a variety of reasons.  Indeed, increasing globalization may weaken the cumulative 
effects that place has on health.  Nonetheless, many people still reside and work in the same 
place for many years.  This pattern is particularly pronounced in rural areas.”208 Moreover, the 
populations of developing economies more heavily influenced by ancestry, race, and ethnicity 
than the population in North American Europe have been largely excluded in biomedical R&D 
even when they are recipients of resulting biopharmaceuticals, and many of their most pressing 
health care needs continue to be unmet and relatively low priorities in ongoing biomedical 
R&D.209 
Completion of the map of the human genome has raised appreciation for the extent to 
which, especially over time, shared environmental exposures can make a collective genetic 
difference—perhaps most notable through advancement in the field of epigenetics.210 The map 
has illuminated a universe of intricacies, complexities, and subtleties in human genetics beyond 
the appreciation of most prior to its completion.211 Consequently, the map has shifted 
perspective and increased comprehension of the influence of environment exposures in the study 
 
207 This point has been persuasively articulated by Dr. Bhopal in the context of epidemiology and conceded by 
Professors Lillquist and Sullivan.  See generally Bhopal, Responsible Use, supra note 6.  See Sullivan & Lillquist, 
Legal Regulation, supra note 9, at 537-538.  
 
208 Foster, Analyzing Race, supra note 9, at 508.  
 
209 See generally Daar & Singer, Pharmacogenetics, supra note 105, at 242-246. 
 
210 See supra notes 21-22, 53, 117, 110 and accompanying text. 
 
211 See supra notes 38-40, 102-118 and accompanying text. 
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of gene expression, and it has inspired research within populations grouped over time by social 
and cultural notions of race and ethnicity.212 
The approach is supported by significant past success engaging in genetics research 
within groups identified by the social constructs race, ethnicity, and religion, including the 
country members of The Pan Asian Initiative and their populations,213 as well as populations of 
Ashkenazi Jews, Amish, and Mormons within the U.S.214 There are ample examples of disease 
rate differences documented with sound epidemiological data that correlate with groupings based 
upon race and ethnicity.215 The intricacies of human genetics have shifted much genomics 
research up to the population level on par with traditional epidemiological research.216 
Moreover, biotechnology has begun to introduce a generation of biopharmaceuticals developed 
around specific genetic alleles,217 including precedent for developing and delivering medicines 
 
212 The most notable example is HMP.  See supra notes 100-106 and accompanying text. 
 
213 See supra note 112-117 and accompanying text. 
 
214 See supra notes 95-98, 102-118 and accompanying text. 
 
215 See generally Daar & Singer, Pharmacogenetics, supra note 105, at 242-246; Bhopal, Responsible Use, supra 
note 6; Working Group, Use, supra note 14.  See also infra notes 95-98 and accompanying text. 
 
216 See supra notes 32-50 and accompanying text. 
 
217 See generally Kristin Cho, Personalized Prescriptions, Legal Actions Will Help Determine the Success of Using 
Genetics to Improve Drug Treatments, 92 ABA J. 42 (Sept. 2006).  One of the most prominent examples is over 
expression of the Her2neu protein associated with an aggressive form of breast cancer, which inspired development 
of the drug Herceptin and an associated genetic test.  See generally ROBERT BAZELL, HER-2: THE MAKING OF 
HERCEPTIN, A REVOLUTIONARY TREATMENT FOR BREAST CANCER (1998).  A recent example is FDA’s market 
approval of a genetic test that predicts the likelihood of breast cancer returning within 5-10 years after an initial 
cancer.  FDA News, FDA Clears Breast Cancer Specific Molecular Prognostic Test (Feb. 6, 2007), available at 
http://www.fda.gov/bbs/topics/NEWS/2007/NEW01555.html (last visited May 12, 2007). This is the first test 
cleared by the FDA that profiles genetic activity. Id. Two additional recent examples include response differences 
to Warfin, a drug used to stop blood clots from forming and growing, associated with particular alleles and the same 
regarding mercaptopurine (6MP), a drug used in the treatment of acute lymphoblastic leukemia--a childhood 
leukemia.  See generally Jeffrey L. Moe, Commercialization Considerations for Individualized Diagnostic and Drug 
Therapies Resulting from Pharmacogenomics, 66 LA. L. REV. 103 (2005).  However, the biopharmaceutical sectors 
have demonstrated reluctance introducing pharmacogenomic data, and the medical profession has demonstrated 
some reluctance working predictive genetic testing into the delivery of care.  See generally id; Woodcock, 
Pharmacogenomic Data, supra note 118.  Physicians balked at a required 6MP test due to cost and confidence that 
they could identify slow metabolizers of the drug simply by monitoring blood levels.  See id. 
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with attention to genetic differences that are associated with race.218 Race-based research is 
generating results—increased understanding about diseases, such as MS,219 and the means to 
make biopharmaceuticals help and avoid harm in groups organized by race and ethnicity.220 
The law and social science opponents to race-based genetics research challenge the 
soundness of the underlying science.221 They also draw heavily from the legacy of use of 
classification based upon race and ethnicity, both inside and outside of the biomedical context, to 
discriminate and exclude and, when combined with science, to exploit and affirm racist notions 
of inferiority.222 Rounding up and focusing upon this legacy, a strong argument can be made that 
the social dangers of race-based genetics research are too great to justify, especially given 
alternative research methodologies—most notably, disease based and allele-specific population 
genetics.223 
Incendiary debate and ongoing critiques, especially in an age of global communication 
and unprecedented transparency, police use of race-based genetics research and the integrity of 
associated research.224 The professional consequences to Dr. Watson from his words attest to the 
same.225 This check accompanies a trilogy of considerations that support responsible race and 
 
218 See the discussion of BiDil, supra notes 109-123 and accompanying text. 
 
219 See supra notes 105-108. 
 
220 See supra notes 122, 153-156 (Bidil), 109-117 (Theraflu in Asian populations) and accompanying text. 
 
221 See supra notes 53-57 and accompanying text. 
 
222 See supra notes 57-58 and accompanying text.  See, e.g., Roberts, Legal Constraints, supra note 9.  
 
223 Cf. Lillquist & Sullivan, Regulations, supra note 9; Lillquist & Sullivan, Racial Profiling, supra note 9; 
Hoffman, Unraveled, supra note 9.  
 
224 See supra notes 8-9 and Part III. 
 
225 See supra notes 1-3 and accompanying text. 
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ethnicity-based genetics research, each of which is discussed below.  First, strict adherence to 
thoughtful application of bioethics law and policy demands maximum communication with 
potential research subjects and full consideration of the impact of proposed research on study 
participants.226 Recognition of race and ethnicity from the individual subject’s perspective—
sensitivity towards an individual’s association with a particular race and the impact of race and 
ethnicity on one’s self-identification—is fundamental to maximize communication and fully 
assess the impact upon potential subjects, both individually and collectively.227 Second, directly 
recognizing, addressing, and understanding race and ethnicity is a means to confront and offset a 
legacy of discrimination through responsible inclusion in biomedical research, which is 
consistent with the pragmatic exercise of sample collection so necessary in an age of population 
genetics.228 Third, advancement of responsible race and ethnicity-based genetics research is 
consistent with the science arguments of its opponents as well as its proponents.229 
A. Bioethics 
 
The National Institutes of Health (NIH), the Food and Drug Administration (FDA), and 
institutional review boards (IRBs) should scrutinize research protocol proposals for race-based 
 
226 See infra Part V.A. 
 
227 As recognized by the American Medical Association Council on Ethical and Judicial Affairs, “The patient’s right 
of self-decision can be effectively exercised only if the patient possesses enough information to enable an intelligent 
choice.”  Statement of the American Medical Association Council on Ethical and Judicial Affairs (adopted by the 
House of Delegates, Mar. 1981), available at http:/www.ama.-assn.org/ceja (last visited July 12, 2007). See 
generally CARL. H. COLEMAN, JERRY A. MENIKOFF, ET AL., THE ETHICS AND REGULATION OF RESEARCH WITH 
HUMAN SUBJECTS (2005). 
228 See infra Part V.B. 
 
229 See infra Part V.C. 
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genetics research and oversee the research they enable to ensure compliance with regulations to 
protect human subjects.230 Existing law requires nothing less.231 
The regulations to protect human subjects favor race consciousness over race neutrality in 
fundamental ways.  First, population genetics necessitates the collection of large numbers of 
samples with accompanying medical information.232 The connection to medical information 
means that samples are identifiable, even if encrypted, which triggers the informed consent 
requirement.233 Voluntary, informed consent is the touchstone tenet of applied bioethics, as 
recognized in the Nuremberg Code,234 Declaration of Helsinki,235 and Belmont Report,236 and as 
codified in U.S. law under the Common Rule237 and FDA regulations.238 
230 The Common Rule requirements are triggered whenever research is federally funded, or conducted by an 
institution that receives federal funding and has filed an assurance that it will conduct all research in a manner that 
complies.  See generally Common Rule, 45 C.F.R. § 46 (2005), and separate Food and Drug Administration 
regulations, 21 C.F.R. § 50.20 (2005).  See also Bonnie M. Lee, U.S. Food and Drug Administration, Comparison of 
FDA and HHS Human Subject Protection Regulations, 2000, available at http:// 
www.fda.gov/oc/gcp/comparison.html (last visited June 7, 2007); Food and Drug Administration regulations, 21 
C.F.R. § 50.20 (2005).  See also Bonnie M. Lee, U.S. Food and Drug Administration, Comparison of FDA and HHS 
Human Subject Protection Regulations, 2000, available at http:// www.fda.gov/oc/gcp/comparison.html (last visited 
June 9, 2007); Coleman, supra note 173.   
231 See id. For guidance on application of human subjects protection regulations, see NIH, Research on Hman 
Subjects, available at http://www.cdp.ims.nci.nih.gov/brochure.html (last visited May 7, 2007).  See also the Office 
for Human Subjects Research Protections, Human Subject Regulations Decision Charts, available at 
http://www.hhs.gov/ohrp/humansubjects/guidance/decisioncharts.htm (last visited May 7, 2007). 
 
232 Yoon, Prediction, supra note 48.  Cf generally MARTIN & MORRISON, supra note 38. 
 
233 The requirements are triggered when samples are identifiable, even if encrypted, but IRBs may wave the 
requirement where subjects are exposed to minimum risk.   See Decision Charts, supra note 177. 
 
234 The Nuremberg Code, in 2 Trials of the War Criminals Before the Nuremberg Military Tribunals Under Control 
Council Law No. 10, 181-82 (Government Printing Office, 1949), available at http:// 
www.hhs.gov/ohrp/references/nurcode.htm (last visited May 12, 2007).
235 World Med. Ass'n, Declaration of Helsinki 1964), http:// www.wma.net/e/policy/pdf/17c.pdf (last visited May 
12, 2007).
236 Ethical Principles and Guidelines for the Protection of Human Subjects of Research, at http:// 
ohsr.od.nih.gov/mpa/belmont.php3 (Apr. 18, 1979) (last visited May 17, 2007).
237 See generally 45 C.F.R. pt. 46 (2005). 
 
238 21 C.F.R. §§ 50, 56 (2005). 
Field Code Changed
54
The realization of informed consent presupposes meaningful communication—a meeting 
of the minds between study sponsors and subjects.239 Recognition of race and ethnicity from the 
individual subject’s perspective—sensitivity towards whether the individual self-identifies with a 
particular race or not—is fundamental to maximize communication and to fully assess the impact 
upon potential subjects, both individually and collectively.  As explored through Critical Race 
Theory in the law literature for decades240 and in the social sciences for much longer,241 race and 
ethnicity often have a profound impact on how people self-identify, interpret information, and 
relate with others and society in general.242 “Arguably, classifying people using large-scale 
categories such as `African-American’ or  `Native American’ can be helpful in understanding 
community practices with respect to external sources of care, because such practices are based 
on conditions of discrimination and economic disparity that are more or less consistent 
throughout the United States.”243 An interesting recent phenomenon that underscores this point 
is the receptiveness of African Americans to genetic ancestry services, which has been explained 
as a desire to bridge the gap in recorded ancestry attributable to slavery.244 
239 See generally 45 C.F.R. §46.116(a); TOM L. BEAUCHAMP & RUTH R. FADEN, INFORMED CONSENT: MEANING 
AND ELEMENTS, IN 3 ENCYCLOPEDIA OF BIOETHICS 1277, 1279 (3d ed. 2004). 
 
240 See, e.g., Mari Matsuda, Voices of America:  Accent, Antidiscrimination Law, and a Jurisprudence for the Last 
Reconstruction, 100 YALE L. J. 1329 (1991).   
 
241 Ossorrio, About Face, supra note 5, at 279.   
 
242 See generally Cheryl I Harris, Whitewashing Race: Scapegoating Culture, 94 CAL. L. REV. 907 (2006); Cheryl I. 
Harris, Critical Race Studies: An Introduciton, 49 UCLA L. REV. 1215 (2002).    
 
243 Foster, Analyzing Race, supra note 9, at 509-510. 
 
244 See generally John Simons, Out of Africa, 155 FORTUNE 37 (Feb. 19. 2007) (“African Ancestry's business has 
doubled in each of the past four years; all told, it has served 10,000 customers.”).  An estimated 460,000 people in 
the U.S. have taken genetic tests to determine ancestry even though they cost hundreds of dollars and individually 
provide incomplete pieces of information.   See Ron Nixon, DNA Tests, Find Branches But Few Roots, N.Y. TIMES,
Nov. 25, 2007, at 1, 7 (identifying companies engaged in genetic research to trace ancestry).  “The demand has 
spawned an industry.  Almost two dozen companies now offer such services, up from just two or three only six 
years ago.  The field is so hot that private equity investors have moved in: Spectrum Equity Investors recently 
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In addition to individual consent, HMP and other population genetics efforts have raised 
recognition of the importance of group consent, and HMP has generated some algorithms for 
obtaining it.245 Group consent is necessitated by the reality of group harm.  In fact, the National 
Geographic Society’s project to collect 100,000 indigenous DNA samples to trace migrations 
patterns of the human species, the Genographic Project, was suspended while an Institutional 
Review Board at the University of Pennsylvania worked on the informed consent process.246 
Directly addressing race and ethnicity in population genetics is a means to fully assess group 
impact, including group harm, and to develop this second dimension of consent. 247 
Bioethics also demands full deliberation of the racial and ethnic composition of study 
subjects.  Specifically, the Common Rule and NIH regulations incorporate the fundamental 
ethics principles identified in the Belmont Report. 248 Justice, the second of the three principles, 
 
bought Ancestry.com, an online geneology site, for about $300 million shortly after the site added genetic testing as 
a service.”  Id. at 7.  For one of the many companies offering these services, visit DNAPrint Genomics, Ancestry by 
DNA, available at http://www.ancestrybydna.com/ (last visited March 3, 2007).  The impact of race and ethnicity on 
self and social identification is captured in Motherland: A Genetic Journey, a documentary by the British 
Broadcasting System, which follows three people who participated in a study allowing subjects with African 
features to use contemporary genetics to trace their ancestry.   See generally BBC, Motherland: A Genetic Journey 
(Feb. 14, 2003). The impact of the results on these individuals’ self-identification was profound and often 
unpredictable from the subjects’ perspectives.  See id. 
245 See Clayton, Implications, supra note 35.  See generally supra note 17.  The U.K. effort to build a biobank of 
biological, environmental, and medical data from 500,000 individuals qged 40-69 also has generated much ethics 
consideration and guidance.  See generally UK Biobank Ethics and Governance Council, Annual Report 2004-2005 
(2006).  
 
246 See Amy Harmon, Question Stalls DNA Tracking: What’s the Benefit for the Tribe?, N.Y. TIMES, Dec. 10, 2006, 
at A1, A30.  Visit the Genographic Project home page at 
https://www3.nationalgeographic.com/genographic/index.html (last visited Mar. 19, 2007). The project quickly 
generated group harm to the Havasupai tribe in the form of identity confusion, and virtually all tribes in North 
America recognized by the federal government have refused to participate.  See Harmon, supra note 9, at A1, A30.  
The tribe’s ancestors were linked to Asia, while tribe members have been raised to believe the Grand Canyon is the 
birthplace of humanity.  Id. 
247 See Clayton, Implications, supra note 35.  See generally supra note 17.   
248 See supra note 74 and accompanying text; The Belmont Report, Ethical Principles and Guidelines for the 
Protection of Human Subjects in Research (Apr. 18, 1979), available at NIH, Office of Human Subjects Research, 
http://ohsr.od.nih.gov/guidelines/belmont.html (last visited June 10, 2007). 
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demands recognition of race and ethnicity for research impact assessment and that such 
assessment be undertaken.  As explained in the Report, 
[T]he selection of research subjects needs to be scrutinized in order to determine 
whether some classes (e.g., welfare patients, particular racial and ethnic 
minorities, or persons confined to institutions) are being systematically selected 
simply because of their easy availability, their compromised position, or their 
manipulability, rather than for reasons directly related to the problem being 
studied. Finally, whenever research supported by public funds leads to the 
development of therapeutic devices and procedures, justice demands both that 
these not provide advantages only to those who can afford them and that such 
research should not unduly involve persons from groups unlikely to be among the 
beneficiaries of subsequent applications of the research.249 
In accordance with the justice principle, NIH rules require researchers to describe the 
composition of study populations and to provide a rationale for subject selection.250 The realities 
of race and ethnicity are utilized to police against discrimination and exclusion, the very 
concerns fueling opposition to race-based genetics research.251 
B. Research Pragmatism and a Means for Access 
 
The social constructs of race and ethnicity, like genetic science, are neither intrinsically 
good nor bad.  Their social impact depends upon how they are used.  The ethical, legal, and 
social legacies of race and genetics are damning,252 especially at their nexus, which mandates 
caution moving forward.253 However, learning from the past and proceeding with caution must 
be distinguished from allowing the past to control the future, especially when the context is 
 
249 Belmont, supra note 193, at Prin. III. 
.
250 See supra note 75 and accompanying text. 
 
251 See id. Even Professor Dorothy Roberts, who is strongly opposed to race-based biomedical research, is 
supportive of the use of race and ethnicity as sociopolitical classifications in order to counteract exclusion of these 
groups and health care disparities.  Roberts, Legal Constraints, supra note 6, at 532-533.   See also supra note 123.  
 
252 See supra note 15 and accompanying text.  
253 See generally Duster, Lessons, supra note 57; Hoffman, Unraveled, supra note 6; Roberts, Legal Constraints,
supra note 6. 
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human health and there are opportunities to include where there has been exclusion, to lessen 
health care disparities, and to improve human health.254 
Making medical sense out of the map of the human genome map necessitates accessing 
samples and medical information.255 Race and ethnicity are strong influences on how 
populations are organized and self-identify,256 especially in developing economies, 257 and 
utilization of such groupings could provide a means for the extensive sample collection 
necessary to advance the translation of the map into medical meaning.258 Research pragmatism, 
the simple act of approaching and interacting with populations to collect needed samples and 
accompanying medical information on acceptable terms, favors recognizing and embracing race 
and ethnicity.  Moreover, groups organized by race and ethnicity, such as country participants in 
The Pan Asian Initiative, have an unprecedented opportunity to leverage their organization to 
draw research to their priority areas, and do so on terms favorable to them.259 Research 
contributions are being made, such as enablement of the MS study mentioned earlier260 and race-
based research to improve the efficacy and safety of biopharmaceuticals for the groups 
 
254 Daar & Singer, Pharmacogenetics, supra note 105, at 242-246. 
 
255 See supra Part II.C.  Cf. generally MARTIN & MORRISON, supra note 38. 
 
256 See supra notes 14, 157-160 and accompanying text. 
 
257 Daar & Singer, Pharmacogenetics, supra note 105, at 242-246. 
 
258 See Yoon, supra note 49, at 40.  See generally Knoppers, International Norms, supra note 12.  
 
259 See supra note 147 (PXE case study).   
 
260 See supra notes 105-108 (MS study).  Howard University’s biobank is profiled in Motherland, supra note 189, 
when Howard’s relatively sophisticated database is used to clarify some confusion for one of the subjects attempting 
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has been administratively shifted to its clinical center due in part to difficulties recruiting participants.   
Communication between Damon Bowe and Howard University Administrators, November 13, 2007.  See also 
Kaiser, J., GENETICS: U.S. Hospital Launches Large Biobank of Children's DNA, 312 SCIENCE 1584a-1585 (2006).  
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involved.261 “Racial and ethnic categories can be particularly important in securing resources to 
reduce structural barriers to prevention and care, especially where racial and ethnic categories are 
embedded in health care and research infrastructure and policy.”262 Globally, the need for 
change could not be greater:  “Only 16 of the 1,393 new drugs that were marketed between 1975 
and 1999 were registered for diseases that predominantly affect people in developing countries, 
and through of those were for tuberculosis, which is not restricted to developing countries.”263 
Singling groups out on the basis of race and ethnicity to benefit their health is desirable, 
presumably a legitimate state interest, and not discrimination for the purposes of U.S. 
antidiscrimination jurisprudence.264 It follows that, within the discipline of law, race and 
ethnicity in genetics research should be approached with the mindset of responsible bioethics and 
affirmative action/inclusion, not with a presumption of discrimination. We should think openly 
in terms of race and ethnicity to raise participation in the genomics revolution.  Professor 
Hoffman’s proposed attributes-based identification runs contrary to a function-based approach to 
affirmative action, which is premised upon recognizing race meaningfully in order to accomplish 
objectives such as inclusion and diversification.265  “Prohibiting the use of racial identity labels 
 
261 See infra notes 122, 153-156 (Bidil in African Americans); 109-117 (Theraflu in Asian populations). 
 
262 Foster, Analyzing Race, supra note 5, at 512. 
 
263 Daar & Singer, Pharmacogenetics, supra note 105, at 243. 
 
264 See generally Grutter, 539 U.S. at 306.  But see generally Seattle School District, supra note 89, and 
accompanying text. 
 
265 See Hoffman, Unraveled, supra note 5. See generally  Tseming Yang, In Affirmative Action, the Census, and a 
Colorblind Society, 11 MICH. J. RACE & L. 367, 402-415 (2006).  In contrast, FDA policy demands recognition of 
U.S. Census classifications in order to promote inclusion where there has been exclusion.  See Daar & Singer, 
Pharmacogenetics, supra note 105, at 242.     
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and ignoring prejudice and discrimination will not make them disappear. The very persistence of 
discrimination creates a need for a tool to monitor and redress its effects.”266 
C. The Underlying Science 
 
Race-based research is producing results—results that include increased understanding of 
diseases such as MS and explanations for the prevalence of adverse events from common 
biopharmaceuticals in populations organized by race and ethnicity.267 Nevertheless, ironically, 
advancement of responsible race and ethnicity-based genetics research also is consistent with the 
scientific arguments of its opponents, as illustrated by the lpBiobank case study.268 To the extent 
opponents are proven correct, research outcomes and associated health care applications will 
transcend the racial and ethnic groups under study to benefit the entire human species.  
Advancement of the research will establish the extent to which race and ethnicity are genetic 
fictions.  Groups organized by race and ethnicity will gain the opportunity to bargain for 
inclusion with both the science and medical communities, and the doctrine of group consent will 
be further developed.269 To the extent the critics are incorrect, the groups under study will 
benefit disproportionately through scientific understanding and greater likelihood of medicinal 
applications tailored to their genetic idiosyncrasies. 
The law, bioethics, and social science communities have raised concerns that the fluidity 
of race and ethnicity make them scientifically imprecise enough to necessitate regulating them 
 
266 Id. at 416. 
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268 See generally supra Part IV. 
 
269 For discussion of supportive case studies, including PXE, see generally Winickoff, supra note 148; Malinowski, 
Technology Transfer, supra note 37. 
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away from many biomedical research purposes.270 These concerns embody several 
presumptions about the natural science communities.  First, they presume that the natural science 
communities are incapable of accounting for the imprecision of what they recognize to be social 
constructs.271 Second, they presume that the natural science and medical communities are not 
capable of policing the validity of scientific claims that arise from race and genetics-based 
research and engaging in meaningful, ongoing peer review.  In fact, the natural science and 
medical communities utilize peer review extensively, in contrast with legal academia, which 
entrusts most journal publication selection and production to law students.  Third, they presume 
that it is not possible to carry out race and ethnicity based research with responsible application 
of bioethics and sensitivity to group impact.   
 In fact, the immediate, definitive, and global response to Dr. Watson’s comments about 
genetics and race272 and the rigorous debate over this research within the natural science and 
medical communities suggest the contrary.273 The broader debate within the global science, 
medical, bioethics, law, sociology, and other social science communities provides an even firmer 
check on the integrity of resulting claims and the threat of abuse of science for social injustice.274 
The role of law and policy in this debate should be to enforce regulations that protect human 
subjects to ensure race-based genetics research is carried out in a responsible manner, meaning 
with attention to consequences for individual subjects and the groups they represent.   
 
270 See, e.g., Cho, Bathwater, supra note 57. 
 
271 See supra notes 3, 19-25 and accompanying text.  
 
272 See supra notes 1-3 and accompanying text. 
 
273 See generally supra note 9. 
 
274 See generally supra notes 9-10 
.
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VI. Conclusion 
 
Race-based genetics research is advancing understanding about human disease and 
directly benefiting populations under study.275 Entire nations are organizing themselves to reap 
these benefits, both individually and collectively.276 
Law is largely a reflective endeavor; the precedent of the past is highly influential and 
often persuasive.   However, mistakes of the past should not determine the present nor the future 
of genetic science and medicine, especially given the opportunities for inclusion and to improve 
human health associated with responsible genetics research.277 Rather than allowing past 
mistakes in scientific research and medicine and a legacy of discrimination and exploitation 
based on race and ethnicity to shackle science, the law should be applied to ensure that research, 
including race, ethnicity, and ancestry-based population genetics, advances responsibly. 
This article has analyzed the use of race and ethnicity in genetics research with sensitivity 
to past controversies and present inequities, but with an emphasis on applied bioethics, scientific 
pragmatism, and ongoing biopharmaceutical R&D.  A major theme is that the lines between 
natural genetics science and the social sciences should not be made too faint and fluid.  Doing so 
from the base of natural genetic science invites speculation about genetic truths and introduces 
susceptibility to prejudices.  Doing so from the base of the social sciences invites overreaching 
far beyond the existing state of genetic science and the substitution of speculation for scientific 
reality in areas fundamental to human health and society.      
 
275 See, e.g., supra notes 112-118, 105-108, 109-117, 122, 153-156. 
 
276 See, e.g., supra notes 112-117, 213 (Pan Asian Initiative). 
 
277 This opportunity is illustrated through the lpBiobank hypothetical case study presented in Part IV and several real 
world case studies addressed in Winickoff, supra note 147 and Malinowski, Technology Transfer, supra note 37.  
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The article’s proposal promotes several important goals: heightened sensitivity towards 
people’s self-identification, group identification, and group impact in the context of population 
genetics research on human subjects;278 an increase in the rate of translation of the map of the 
human genome into medical meaning through more group participation in biomedical 
research;279 an increase in participation in the genomics revolution by groups organized socially 
and culturally by race and ethnicity;280 and a lessening of negative, documented disparities in the 
delivery of health care for these groups.281 
Responsible race-based research is possible and desirable, and the law should be applied 
to accomplish nothing less.   This position rests solidly on footings of applied bioethics,282 
research pragmatism, 283 and natural science.284 Proposals to stretch U.S. antidiscrimination 
jurisprudence to regulate away the use of race and ethnicity in genetics research are misguided at 
best.             
 
278 See supra Part V.A. 
 
279 See supra Part V.B. 
 
280 See supra Parts IV, V.B, and V.C. 
 
281 See supra Parts V.B and V.C. 
 
282 See supra Part V.A 
 
283 See supra Part V.B 
 
284 See supra Part V.C 
